Header Logo

STEVEN M KORNBLAU

TitleProfessor
InstitutionMD Anderson
DepartmentLeukemia
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Huang X, Li Y, Zhang J, Yan L, Zhao H, Ding L, Bhatara S, Yang X, Yoshimura S, Yang W, Karol SE, Inaba H, Mullighan C, Litzow M, Zhu X, Zhang Y, Stock W, Jain N, Jabbour E, Kornblau SM, Konopleva M, Pui CH, Paietta E, Evans W, Yu J, Yang JJ. Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemia. Cancer Cell. 2024 Apr 08; 42(4):552-567.e6. PMID: 38593781; PMCID: PMC11008188.
      Citations:    
    2. Bose P, Masarova L, Pemmaraju N, Bledsoe SD, Daver NG, Jabbour EJ, Kadia TM, Estrov Z, Kornblau SM, Andreeff M, Jain N, Cortes JE, Borthakur G, Alvarado Y, Richie MA, Dobbins MH, McCrackin SA, Zhou L, Pierce SA, Wang X, Pike AM, Garcia-Manero G, Kantarjian HM, Verstovsek S. Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study. Haematologica. 2024 Apr 04. PMID: 38572554.
      Citations:    Fields:    
    3. de Camargo Magalh?es ES, Hubner SE, Brown BD, Qiu Y, Kornblau SM. Proteomics for optimizing therapy in acute myeloid leukemia: venetoclax plus hypomethylating agents versus conventional chemotherapy. Leukemia. 2024 Mar 26. PMID: 38531950.
      Citations:    Fields:    
    4. Bazinet A, Garcia-Manero G, Short N, Alvarado Y, Bataller A, Abuasab T, Islam R, Montalbano K, Issa G, Maiti A, Yilmaz M, Jain N, Masarova L, Kornblau S, Jabbour E, Montalban-Bravo G, Rausch CR, Pierce S, DiNardo CD, Kadia T, Daver N, Konopleva M, Huang X, Kantarjian H, Ravandi F. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study. Lancet Haematol. 2024 Apr; 11(4):e276-e286. PMID: 38452788.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    5. Barnett KR, Mobley RJ, Diedrich JD, Bergeron BP, Bhattarai KR, Monovich AC, Narina S, Yang W, Crews KR, Manring CS, Jabbour E, Paietta E, Litzow MR, Kornblau SM, Stock W, Inaba H, Jeha S, Pui CH, Mullighan CG, Relling MV, Pruett-Miller SM, Ryan RJH, Yang JJ, Evans WE, Savic D. Epigenomic mapping reveals distinct B cell acute lymphoblastic leukemia chromatin architectures and regulators. Cell Genom. 2023 Dec 13; 3(12):100442. PMID: 38116118; PMCID: PMC10726428.
      Citations:    
    6. Kimura S, Polonen P, Montefiori L, Park CS, Iacobucci I, Yeoh AE, Attarbaschi A, Moore AS, Brown A, Manabe A, Buldini B, Freeman BB, Chen C, Cheng C, Kean Hui C, Li CK, Pui CH, Qu C, Tomizawa D, Teachey DT, Varotto E, Paietta EM, Arnold ED, Locatelli F, Escherich G, Elisa Muhle H, Marquart HV, de Groot-Kruseman HA, Rowe JM, Stary J, Trka J, Choi JK, Meijerink JPP, Yang JJ, Takita J, Pawinska-Wasikowska K, Roberts KG, Han K, Caldwell KJ, Schmiegelow K, Crews KR, Eguchi M, Schrappe M, Zimmerman M, Takagi M, Maybury M, Svaton M, Reiterova M, Kicinski M, Prater MS, Kato M, Reyes N, Spinelli O, Thomas P, Mazilier P, Gao Q, Masetti R, Kotecha RS, Pieters R, Elitzur S, Luger SM, Mitchell S, Pruett-Miller SM, Shen S, Jeha S, K?hrer S, Kornblau SM, Skoczen S, Miyamura T, Vincent TL, Imamura T, Conter V, Tang Y, Liu YC, Chang Y, Gu Z, Cheng Z, Yinmei Z, Inaba H, Mullighan CG. Biologic and clinical features of childhood gamma delta T-ALL: identification of STAG2/LMO2 ?d T-ALL as an extremely high risk leukemia in the very young. medRxiv. 2023 Nov 08. PMID: 37986997; PMCID: PMC10659466.
      Citations:    
    7. Rowland L, Smart B, Brown A, Dettorre GM, Gocho Y, Hunt J, Yang W, Yoshimura S, Reyes N, Du G, John A, Maxwell D, Stock W, Kornblau S, Relling MV, Inaba H, Pui CH, Bourquin JP, Karol SE, Mullighan CG, Evans WE, Yang JJ, Crews KR. Ex vivo Drug Sensitivity Imaging-based Platform for Primary Acute Lymphoblastic Leukemia Cells. Bio Protoc. 2023 Aug 05; 13(15):e4731. PMID: 37575398; PMCID: PMC10415213.
      Citations: 1     
    8. Barnett KR, Mobley RJ, Diedrich JD, Bergeron BP, Bhattarai KR, Yang W, Crews KR, Manring CS, Jabbour E, Paietta E, Litzow MR, Kornblau SM, Stock W, Inaba H, Jeha S, Pui CH, Mullighan CG, Relling MV, Yang JJ, Evans WE, Savic D. Epigenomic mapping in B-cell acute lymphoblastic leukemia identifies transcriptional regulators and noncoding variants promoting distinct chromatin architectures. bioRxiv. 2023 Jul 13. PMID: 36824825; PMCID: PMC9949063.
      Citations:    
    9. Senapati J, Muftuoglu M, Ishizawa J, Abbas HA, Loghavi S, Borthakur G, Yilmaz M, Issa GC, Dara SI, Basyal M, Li L, Naqvi K, Pourebrahim R, Jabbour EJ, Kornblau SM, Short NJ, Pemmaraju N, Garcia-Manero G, Ravandi F, Khoury J, Daver N, Kantarjian HM, Andreeff M, DiNardo CD. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. Blood Cancer J. 2023 06 29; 13(1):101. PMID: 37386016; PMCID: PMC10310786.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    10. Hoff FW, Qiu Y, Brown BD, Gerbing RB, Leonti AR, Ries RE, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Meshinchi S, Jenkins GN, Horton TM, Kornblau SM. Valosin-containing protein (VCP/p97) is prognostically unfavorable in pediatric AML, and negatively correlates with unfolded protein response proteins IRE1 and GRP78: A report from the Children's Oncology Group. Proteomics Clin Appl. 2023 Nov; 17(6):e2200109. PMID: 37287368; PMCID: PMC10700663.
      Citations:    Fields:    
    11. Carter BZ, Mak PY, Tao W, Ayoub E, Ostermann LB, Huang X, Loghavi S, Boettcher S, Nishida Y, Ruvolo V, Hughes PE, Morrow PK, Haferlach T, Kornblau S, Muftuoglu M, Andreeff M. Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics. Blood Cancer J. 2023 May 17; 13(1):80. PMID: 37193700; PMCID: PMC10188521.
      Citations:    Fields:    
    12. Short NJ, Jabbour E, Macaron W, Ravandi F, Jain N, Kanagal-Shamanna R, Patel KP, Loghavi S, Haddad FG, Yilmaz M, Issa GC, Kebriaei P, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Kantarjian H. Ultrasensitive NGS MRD assessment in Ph+?ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1. Am J Hematol. 2023 08; 98(8):1196-1203. PMID: 37183966.
      Citations:    Fields:    Translation:Humans
    13. Carter BZ, Mak PY, Tao W, Ayoub E, Ostermann LB, Huang X, Loghavi S, Boettcher S, Nishida Y, Ruvolo V, Hughes PE, Morrow PK, Haferlach T, Kornblau S, Muftuoglu M, Andreeff M. Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics. Blood Cancer J. 2023 04 24; 13(1):57. PMID: 37088806; PMCID: PMC10123065.
      Citations:    Fields:    Translation:AnimalsCells
    14. Wright S, Hu J, Wang H, Hyle J, Zhang Y, Du G, Konopleva MY, Kornblau SM, Djekidel MN, Rosikiewicz W, Xu B, Lu R, Yang JJ, Li C. Interrogating bromodomain inhibitor resistance in KMT2A-rearranged leukemia through combinatorial CRISPR screens. Proc Natl Acad Sci U S A. 2023 04 18; 120(16):e2220134120. PMID: 37036970; PMCID: PMC10120025.
      Citations: 1     Fields:    Translation:HumansCells
    15. Ramabadran R, Wang JH, Reyes JM, Guzman AG, Gupta S, Rosas C, Brunetti L, Gundry MC, Tovy A, Long H, Gu T, Cullen SM, Tyagi S, Rux D, Kim JJ, Kornblau SM, Kyba M, Stossi F, Rau RE, Takahashi K, Westbrook TF, Goodell MA. DNMT3A-coordinated splicing governs the stem state switch towards differentiation in embryonic and haematopoietic stem cells. Nat Cell Biol. 2023 04; 25(4):528-539. PMID: 37024683; PMCID: PMC10337578.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    16. Hubner SE, de Camargo Magalh?es ES, Hoff FW, Brown BD, Qiu Y, Horton TM, Kornblau SM. DNA Damage Response-Related Proteins Are Prognostic for Outcome in Both Adult and Pediatric Acute Myelogenous Leukemia Patients: Samples from Adults and from Children Enrolled in a Children's Oncology Group Study. Int J Mol Sci. 2023 Mar 20; 24(6). PMID: 36982970; PMCID: PMC10058043.
      Citations:    Fields:    Translation:HumansCells
    17. Hoff FW, Griffen TL, Brown BD, Horton TM, Burger J, Wierda W, Hubner SE, Qiu Y, Kornblau SM. Reverse Phase Protein Array Profiling Identifies Recurrent Protein Expression Patterns of DNA Damage-Related Proteins across Acute and Chronic Leukemia: Samples from Adults and the Children's Oncology Group. Int J Mol Sci. 2023 Mar 13; 24(6). PMID: 36982537; PMCID: PMC10056740.
      Citations:    Fields:    Translation:Humans
    18. Griffen TL, Hoff FW, Qiu Y, Burger J, Wierda W, Kornblau SM. Prognostication of DNA Damage Response Protein Expression Patterns in Chronic Lymphocytic Leukemia. Int J Mol Sci. 2023 Mar 13; 24(6). PMID: 36982555; PMCID: PMC10049670.
      Citations:    Fields:    Translation:Humans
    19. Konopleva M, DiNardo C, Bhagat T, Baran N, Lodi A, Saxena K, Cai T, Su X, Skwarska A, Guerra V, Kuruvilla V, Konoplev S, Gordon-Mitchell S, Pradhan K, Aluri S, Collins M, Sweeney S, Busquet J, Rathore A, Deng Q, Green M, Grant S, Demo S, Choudhary G, Sahu S, Agarwal B, Spodek M, Thiruthuvanathan V, Will B, Steidl U, Tippett G, Burger J, Borthakur G, Jabbour E, Pemmaraju N, Kadia T, Komblau S, Daver N, Naqvi K, Short N, Garcia-Manero G, Tiziani S, Verma A. Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses. Res Sq. 2023 Feb 23. PMID: 36865338; PMCID: PMC9980221.
      Citations:    
    20. Bhattarai KR, Mobley RJ, Barnett KR, Ferguson DC, Hansen BS, Diedrich JD, Bergeron BP, Yang W, Crews KR, Manring CS, Jabbour E, Paietta E, Litzow MR, Kornblau SM, Stock W, Inaba H, Jeha S, Pui CH, Cheng C, Pruett-Miller SM, Relling MV, Yang JJ, Evans WE, Savic D. Functional investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment. medRxiv. 2023 Feb 11. PMID: 36798219; PMCID: PMC9934807.
      Citations:    
    21. Tantawy SI, Sarkar A, Hubner S, Tan Z, Wierda WG, Eldeib A, Zhang S, Kornblau S, Gandhi V. Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies. Clin Cancer Res. 2023 01 17; 29(2):446-457. PMID: 36346691; PMCID: PMC9852224.
      Citations: 3     Fields:    Translation:HumansCells
    22. Aitken MJL, Malaney P, Zhang X, Herbrich SM, Chan L, Benitez O, Rodriguez AG, Ma H, Jacamo R, Duan R, Link TM, Kornblau SM, Kanagal-Shamanna R, Bueso-Ramos CE, Post SM. Heterogeneous nuclear ribonucleoprotein K is overexpressed in acute myeloid leukemia and causes myeloproliferation in mice via altered Runx1 splicing. NAR Cancer. 2022 Dec; 4(4):zcac039. PMID: 36518526; PMCID: PMC9732523.
      Citations: 2     
    23. Hoff FW, Van Dijk AD, Qiu Y, Hu CW, Ries RE, Ligeralde A, Jenkins GN, Gerbing RB, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Meshinchi S, Qutub AA, De Bont ESJM, Horton TM, Kornblau SM. Clinical relevance of proteomic profiling in de novo pediatric acute myeloid leukemia: a Children's Oncology Group study. Haematologica. 2022 10 01; 107(10):2329-2343. PMID: 35021602; PMCID: PMC9521248.
      Citations: 2     Fields:    
    24. Hoff FW, Griffen TL, Qiu Y, Kornblau SM. Protein profiling by reverse phase protein array (RPPA) in classical hairy cell leukemia (HCL) and HCL-variant. EJHaem. 2022 Nov; 3(4):1321-1325. PMID: 36467805; PMCID: PMC9713071.
      Citations:    
    25. Short NJ, Kantarjian H, Ravandi F, Konopleva M, Jain N, Kanagal-Shamanna R, Patel KP, Macaron W, Kadia TM, Wang S, Jorgensen JL, Khoury JD, Yilmaz M, Kebriaei P, Takahashi K, Garcia-Manero G, Daver N, Post SM, Huang X, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Jabbour E. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv. 2022 07 12; 6(13):4006-4014. PMID: 35533262; PMCID: PMC9278301.
      Citations:    Fields:    Translation:Humans
    26. Thomas GE, Egan G, Botham A, Voisin V, Patel PS, Hoff FW, Chin J, Nachmias B, Kaufmann KB, Khan DH, Hurren R, Wang X, Gronda M, MacLean N, O'Brien C, Singh RP, Jones CL, Harding SM, Raught B, Arruda A, Minden MD, Bader GD, Hakem R, Kornblau S, Dick JE, Schimmer AD, Garc?a-Prat L. The metabolic enzyme hexokinase 2 localizes to the nucleus in AML and normal haematopoietic stem and progenitor cells to maintain stemness. Nat Cell Biol. 2022 06; 24(6):872-884. PMID: 35668135; PMCID: PMC9203277.
      Citations:    Fields:    Translation:HumansCells
    27. DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Kadia T, Daver N, Xiao L, Adeoti M, Short NJ, Sasaki K, Wang SA, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Bravo GM, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Am J Hematol. 2022 08; 97(8):1035-1043. PMID: 35583199.
      Citations: 1     Fields:    Translation:Humans
    28. Andersson BS, Thall PF, Ma J, Valdez BC, Bassett R, Chen J, Ahmed S, Alousi A, Bashir Q, Ciurea S, Gulbis A, Cool R, Kawedia J, Hosing C, Kebriaei P, Kornblau S, Myers A, Oran B, Rezvani K, Shah N, Shpall E, Parmar S, Popat UR, Nieto Y, Champlin RE. A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan???clofarabine in allogeneic stem cell transplantation. Bone Marrow Transplant. 2022 08; 57(8):1295-1303. PMID: 35610308; PMCID: PMC9352570.
      Citations:    Fields:    
    29. Baran N, Lodi A, Dhungana Y, Herbrich S, Collins M, Sweeney S, Pandey R, Skwarska A, Patel S, Kuruvilla VM, Cavazos A, Kaplan M, Warmoes MO, Veiga DT, Furudate K, Ma H, Harutyunyan K, Daher M, Garcia LM, Al-Atrash G, Piya S, Ruvolo V, Yang W, Shanmugavelandy SS, Feng N, Gay J, Du D, Yang JJ, Hoff FW, Kaminski M, Tomczak K, Eric Davis R, Herranz D, Ferrando A, Jabbour EJ, Emilia Di Francesco M, Teachey DT, Horton TM, Kornblau S, Rezvani K, Gagea M, Andreeff M, Takahashi K, Marszalek JR, Lorenzi PL, Yu J, Tiziani S, Konopleva M, Tremblay M, Rojas-Sutterin S, Haman A, Gareau Y, Marinier A, Sauvageau G, Hoang T. Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia. Nat Commun. 2022 05 19; 13(1):2801. PMID: 35589701; PMCID: PMC9120040.
      Citations:    Fields:    Translation:AnimalsCells
    30. Griffen TL, Hoff FW, Qiu Y, Lillard JW, Ferrajoli A, Thompson P, Toro E, Ruiz K, Burger J, Wierda W, Kornblau SM. Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets. Blood Cancer J. 2022 03 17; 12(3):43. PMID: 35301276; PMCID: PMC8931092.
      Citations:    Fields:    Translation:Humans
    31. Mill CP, Fiskus W, DiNardo CD, Birdwell C, Davis JA, Kadia TM, Takahashi K, Short N, Daver N, Ohanian M, Borthakur G, Kornblau SM, Green MR, Qi Y, Su X, Khoury JD, Bhalla KN. Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2. Blood. 2022 02 10; 139(6):907-921. PMID: 34601571; PMCID: PMC8832475.
      Citations: 1     Fields:    Translation:HumansCells
    32. Aslan B, Hubner SE, Fox JA, Taverna P, Wierda WG, Kornblau SM, Gandhi V. Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase. Haematologica. 2022 01 01; 107(1):292-297. PMID: 34498444; PMCID: PMC8719067.
      Citations: 2     Fields:    Translation:HumansCells
    33. Hoff FW, Horton TM, Kornblau SM. Reverse phase protein arrays in acute leukemia: investigative and methodological challenges. Expert Rev Proteomics. 2021 12; 18(12):1087-1097. PMID: 34965151; PMCID: PMC9148717.
      Citations:    Fields:    Translation:HumansCells
    34. Youn M, Smith SM, Lee AG, Chae HD, Spiteri E, Erdmann J, Galperin I, Jones LM, Donato M, Abidi P, Bittencourt H, Lacayo N, Dahl G, Aftandilian C, Davis KL, Matthews JA, Kornblau SM, Huang M, Sumarsono N, Redell MS, Fu CH, Chen IM, Alonzo TA, Eklund E, Gotlib J, Khatri P, Sweet-Cordero EA, Hijiya N, Sakamoto KM. Comparison of the Transcriptomic Signatures in Pediatric and Adult CML. Cancers (Basel). 2021 Dec 14; 13(24). PMID: 34944883; PMCID: PMC8699058.
      Citations:    
    35. El Hussein S, Daver N, Liu JL, Kornblau S, Fang H, Konoplev S, Kantarjian H, Khoury JD. Microsatellite Instability Assessment by Immunohistochemistry in Acute Myeloid Leukemia: A Reappraisal and Review of the Literature. Clin Lymphoma Myeloma Leuk. 2022 06; 22(6):e386-e391. PMID: 34980577.
      Citations:    Fields:    Translation:HumansCells
    36. Butler M, van Ingen Schenau DS, Yu J, Jenni S, Dobay MP, Hagelaar R, Vervoort BMT, Tee TM, Hoff FW, Meijerink JP, Kornblau SM, Bornhauser B, Bourquin JP, Kuiper RP, van der Meer LT, van Leeuwen FN. BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway. Blood. 2021 12 09; 138(23):2383-2395. PMID: 34280258; PMCID: PMC8832462.
      Citations: 2     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    37. Abbas HA, Alaniz Z, Mackay S, Cyr M, Zhou J, Issa GC, Alfayez M, Matthews J, Kornblau SM, Jabbour E, Garcia-Manero G, Konopleva M, Andreeff M, Daver N. Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti-PD-1-based therapy. Blood Adv. 2021 11 23; 5(22):4569-4574. PMID: 34555853; PMCID: PMC8759127.
      Citations: 3     Fields:    Translation:HumansCells
    38. van Dijk AD, Hoff FW, Qiu Y, Gerbing RB, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Meshinchi S, Jenkins GN, de Bont ESJM, Kornblau SM, Horton TM. Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-?B subunit RelA. Proteomics Clin Appl. 2022 03; 16(2):e2100072. PMID: 34719869; PMCID: PMC9041833.
      Citations:    Fields:    Translation:HumansCells
    39. Ramos Perez JM, Patel KP, Loghavi S, Garcia-Manero G, Borthakur G, Jabbour E, Wierda W, Pierce S, Brandt M, Kornblau S, Kadia T, Daver N, DiNardo CD, Jain N, Yilmaz M, Short N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Rivera D, McCue D, Kantarjian HM, Ravandi F. Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy. Leuk Lymphoma. 2022 03; 63(3):672-675. PMID: 34668451.
      Citations:    Fields:    Translation:Humans
    40. Abbas HA, Hao D, Tomczak K, Barrodia P, Im JS, Reville PK, Alaniz Z, Wang W, Wang R, Wang F, Al-Atrash G, Takahashi K, Ning J, Ding M, Beird HC, Mathews JT, Little L, Zhang J, Basu S, Konopleva M, Marques-Piubelli ML, Solis LM, Parra ER, Lu W, Tamegnon A, Garcia-Manero G, Green MR, Sharma P, Allison JP, Kornblau SM, Rai K, Wang L, Daver N, Futreal A. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nat Commun. 2021 10 18; 12(1):6071. PMID: 34663807; PMCID: PMC8524723.
      Citations: 3     Fields:    Translation:HumansCells
    41. van Dijk AD, Griffen TL, Qiu YH, Hoff FW, Toro E, Ruiz K, Ruvolo PP, Lillard JW, de Bont ESJM, Burger JA, Wierda W, Kornblau SM. RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences. Leukemia. 2022 03; 36(3):712-722. PMID: 34625713.
      Citations: 1     Fields:    Translation:Humans
    42. Heltemes-Harris LM, Hubbard GK, LaRue RS, Munro SA, Yang R, Henzler CM, Starr TK, Sarver AL, Kornblau SM, Farrar MA. Identification of mutations that cooperate with defects in B cell transcription factors to initiate leukemia. Oncogene. 2021 10; 40(43):6166-6179. PMID: 34535769; PMCID: PMC8556320.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    43. Alwash Y, Khoury JD, Tashakori M, Kanagal-Shamanna R, Daver N, Ravandi F, Kadia TM, Konopleva M, Dinardo CD, Issa GC, Loghavi S, Takahashi K, Jabbour E, Guerra V, Kornblau S, Kantarjian H, Short NJ. Development of TP53 mutations over the course of therapy for acute myeloid leukemia. Am J Hematol. 2021 11 01; 96(11):1420-1428. PMID: 34351647; PMCID: PMC9167467.
      Citations: 2     Fields:    Translation:Humans
    44. Abbas HA, Mohanty V, Wang R, Huang Y, Liang S, Wang F, Zhang J, Qiu Y, Hu CW, Qutub AA, Dail M, Bolen CR, Daver N, Konopleva M, Futreal A, Chen K, Wang L, Kornblau SM. Decoupling Lineage-Associated Genes in Acute Myeloid Leukemia Reveals Inflammatory and Metabolic Signatures Associated With Outcomes. Front Oncol. 2021; 11:705627. PMID: 34422660; PMCID: PMC8372368.
      Citations: 1     
    45. Kadia TM, Reville PK, Borthakur G, Yilmaz M, Kornblau S, Alvarado Y, Dinardo CD, Daver N, Jain N, Pemmaraju N, Short N, Wang SA, Tidwell RSS, Islam R, Konopleva M, Garcia-Manero G, Ravandi F, Kantarjian HM. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2021 Aug; 8(8):e552-e561. PMID: 34329576; PMCID: PMC8884174.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    46. Griffen TL, Dammer EB, Dill CD, Carey KM, Young CD, Nunez SK, Ohandjo AQ, Kornblau SM, Lillard JW. Multivariate transcriptome analysis identifies networks and key drivers of chronic lymphocytic leukemia relapse risk and patient survival. BMC Med Genomics. 2021 06 29; 14(1):171. PMID: 34187466; PMCID: PMC8243588.
      Citations: 2     Fields:    
    47. Saxena K, Herbrich SM, Pemmaraju N, Kadia TM, DiNardo CD, Borthakur G, Pierce SA, Jabbour E, Wang SA, Bueso-Ramos C, Loghavi S, Tang G, Cheung CM, Alexander L, Kornblau S, Andreeff M, Garcia-Manero G, Ravandi F, Konopleva MY, Daver N. A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. Cancer. 2021 10 15; 127(20):3761-3771. PMID: 34171128.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    48. Montefiori LE, Bendig S, Gu Z, Chen X, Ma X, Murison A, Zeng A, Garcia-Prat L, Dickerson K, Iacobucci I, Abdelhamed S, Hiltenbrand R, Mead PE, Mehr CM, Xu B, Cheng Z, Chang TC, Westover T, Ma J, Stengel A, Kimura S, Qu C, Valentine MB, Rashkovan M, Luger S, Litzow MR, Rowe JM, Wang V, Yin J, Kornblau SM, Hunger SP, Loh ML, Pui CH, Yang W, Crews KR, Roberts KG, Yang JJ, Relling MV, Evans WE, Stock W, Paietta EM, Ferrando AA, Zhang J, Kern W, Haferlach T, Wu G, Dick JE, Klco JM, Haferlach C, Mullighan CG, P?l?nen P, den Boer ML. Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia. Cancer Discov. 2021 11; 11(11):2846-2867. PMID: 34103329; PMCID: PMC8563395.
      Citations: 11     Fields:    Translation:HumansCells
    49. DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian HM. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol. 2021 09 01; 39(25):2768-2778. PMID: 34043428; PMCID: PMC8407653.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    50. Fiskus W, Mill CP, Nabet B, Perera D, Birdwell C, Manshouri T, Lara B, Kadia TM, DiNardo C, Takahashi K, Daver N, Bose P, Masarova L, Pemmaraju N, Kornblau S, Borthakur G, Montalban-Bravo G, Manero GG, Sharma S, Stubbs M, Su X, Green MR, Coarfa C, Verstovsek S, Khoury JD, Vakoc CR, Bhalla KN. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer J. 2021 05 20; 11(5):98. PMID: 34016956; PMCID: PMC8138012.
      Citations: 5     Fields:    Translation:HumansCells
    51. Kaeding AJ, Barwe SP, Gopalakrishnapillai A, Ries RE, Alonzo TA, Gerbing RB, Correnti C, Loken MR, Broderson LE, Pardo L, Le QH, Tang T, Leonti AR, Smith JL, Chou CK, Xu M, Triche T, Kornblau SM, Kolb EA, Tarlock K, Meshinchi S. Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia. Blood Adv. 2021 05 11; 5(9):2350-2361. PMID: 33938941; PMCID: PMC8114558.
      Citations: 3     Fields:    Translation:Humans
    52. Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. 2021 03 01; 106(3):894-898. PMID: 32499238; PMCID: PMC7927994.
      Citations: 13     Fields:    Translation:Humans
    53. Hoff FW, van Dijk AD, Qiu Y, Ruvolo PP, Gerbing RB, Leonti AR, Jenkins GN, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Meshinchi S, de Bont ESJM, Bruggeman SWM, Kornblau SM, Horton TM. Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report. Blood. 2021 02 25; 137(8):1050-1060. PMID: 32959058; PMCID: PMC7907722.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    54. van Dijk AD, Hoff FW, Qiu YH, Chandra J, Jabbour E, de Bont ESJM, Horton TM, Kornblau SM. Loss of H3K27 methylation identifies poor outcomes in adult-onset acute leukemia. Clin Epigenetics. 2021 01 28; 13(1):21. PMID: 33509276; PMCID: PMC7841917.
      Citations: 1     Fields:    Translation:HumansCells
    55. Gocho Y, Liu J, Hu J, Yang W, Dharia NV, Zhang J, Shi H, Du G, John A, Lin TN, Hunt J, Huang X, Ju B, Rowland L, Shi L, Maxwell D, Smart B, Crews KR, Yang W, Hagiwara K, Zhang Y, Roberts K, Wang H, Jabbour E, Stock W, Eisfelder B, Paietta E, Newman S, Roti G, Litzow M, Easton J, Zhang J, Peng J, Chi H, Pounds S, Relling MV, Inaba H, Zhu X, Kornblau S, Pui CH, Konopleva M, Teachey D, Mullighan CG, Stegmaier K, Evans WE, Yu J, Yang JJ. Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. Nat Cancer. 2021 03; 2(3):284-299. PMID: 34151288; PMCID: PMC8208590.
      Citations: 10     Translation:HumansCells
    56. Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. Am J Hematol. 2021 03 01; 96(3):282-291. PMID: 33264443; PMCID: PMC8128145.
      Citations: 15     Fields:    Translation:Humans
    57. Horton TM, Hoff FW, van Dijk A, Jenkins GN, Morrison D, Bhatla T, Hogan L, Romanos-Sirakis E, Meyer J, Carroll WL, Qiu Y, Wang T, Mo Q, Kornblau SM. The effects of sample handling on proteomics assessed by reverse phase protein arrays (RPPA): Functional proteomic profiling in leukemia. J Proteomics. 2021 02 20; 233:104046. PMID: 33212251; PMCID: PMC7877245.
      Citations: 1     Fields:    Translation:Humans
    58. DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020 Oct; 7(10):e724-e736. PMID: 32896301; PMCID: PMC7549397.
      Citations: 62     Fields:    Translation:HumansCTClinical Trials
    59. Major CK, Kantarjian H, Sasaki K, Borthakur G, Kadia T, Pemmaraju N, DiNardo C, Short NJ, Daver N, Jabbour E, Champlin R, Garcia-Manero G, Konopleva M, Andreeff M, Kornblau S, Wierda W, Pierce S, Ravandi F, Cortes J. Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. Leuk Lymphoma. 2020 12; 61(13):3120-3127. PMID: 32755333.
      Citations: 2     Fields:    Translation:Humans
    60. Chae HD, Dutta R, Tiu B, Hoff FW, Accordi B, Serafin V, Youn M, Huang M, Sumarsono N, Davis KL, Lacayo NJ, Pigazzi M, Horton TM, Kornblau SM, Sakamoto KM. RSK inhibitor BI-D1870 inhibits acute myeloid leukemia cell proliferation by targeting mitotic exit. Oncotarget. 2020 Jun 23; 11(25):2387-2403. PMID: 32637030; PMCID: PMC7321696.
      Citations: 2     Fields:    
    61. Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia. 2020 11; 34(11):2914-2924. PMID: 32546726.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    62. Short NJ, Kantarjian H, Kanagal-Shamanna R, Sasaki K, Ravandi F, Cortes J, Konopleva M, Issa GC, Kornblau SM, Garcia-Manero G, Garris R, Higgins J, Pratt G, Williams LN, Valentine CC, Rivera VM, Pritchard J, Salk JJ, Radich J, Jabbour E. Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL. Blood Cancer J. 2020 05 26; 10(5):61. PMID: 32457305; PMCID: PMC7250857.
      Citations: 3     Fields:    Translation:HumansCells
    63. Short NJ, Patel KP, Albitar M, Franquiz M, Luthra R, Kanagal-Shamanna R, Wang F, Assi R, Montalban-Bravo G, Matthews J, Ma W, Loghavi S, Takahashi K, Issa GC, Kornblau SM, Jabbour E, Garcia-Manero G, Kantarjian HM, Estrov Z, Ravandi F. Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. Blood Adv. 2020 04 28; 4(8):1670-1677. PMID: 32324887; PMCID: PMC7189293.
      Citations: 9     Fields:    Translation:Humans
    64. Maiti A, Kantarjian HM, Popat V, Borthakur G, Garcia-Manero G, Konopleva MY, DiNardo CD, Verstovsek S, Andreeff M, Kadia TM, Ajufo HO, Goswamy RV, Blanco C, Velasquez M, Daver NG, Pemmaraju N, Pierce SR, Wierda WG, Kornblau SM, Ravandi F, Cortes JE. Clinical value of event-free survival in acute myeloid leukemia. Blood Adv. 2020 04 28; 4(8):1690-1699. PMID: 32330243; PMCID: PMC7189295.
      Citations: 1     Fields:    Translation:Humans
    65. Mirali S, Botham A, Voisin V, Xu C, St-Germain J, Sharon D, Hoff FW, Qiu Y, Hurren R, Gronda M, Jitkova Y, Nachmias B, MacLean N, Wang X, Arruda A, Minden MD, Horton TM, Kornblau SM, Chan SM, Bader GD, Raught B, Schimmer AD. The mitochondrial peptidase, neurolysin, regulates respiratory chain supercomplex formation and is necessary for AML viability. Sci Transl Med. 2020 04 08; 12(538). PMID: 32269163.
      Citations: 17     Fields:    Translation:HumansCells
    66. DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, Thijssen R, Pomilio G, Ivey A, Salmon JM, Glytsou C, Fleming SA, Zhang Q, Ma H, Patel KP, Kornblau SM, Xu Z, Chua CC, Chen X, Blombery P, Flensburg C, Cummings N, Aifantis I, Kantarjian H, Huang DCS, Roberts AW, Majewski IJ, Konopleva M, Wei AH. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020 03 12; 135(11):791-803. PMID: 31932844; PMCID: PMC7068032.
      Citations: 113     Fields:    Translation:Humans
    67. Autry RJ, Paugh SW, Carter R, Shi L, Liu J, Ferguson DC, Lau CE, Bonten EJ, Yang W, McCorkle JR, Beard JA, Panetta JC, Diedrich JD, Crews KR, Pei D, Coke CJ, Natarajan S, Khatamian A, Karol SE, Lopez-Lopez E, Diouf B, Smith C, Gocho Y, Hagiwara K, Roberts KG, Pounds S, Kornblau SM, Stock W, Paietta EM, Litzow MR, Inaba H, Mullighan CG, Jeha S, Pui CH, Cheng C, Savic D, Yu J, Gawad C, Relling MV, Yang JJ, Evans WE. Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. Nat Cancer. 2020 03; 1(3):329-344. PMID: 32885175; PMCID: PMC7467080.
      Citations: 17     Translation:HumansAnimals
    68. Ohanian M, Kornblau S, Ruvolo P, Tidwell RSS, Plesa A, Kanagal-Shamanna R, Matera EL, Cortes J, Carson A, Dumontet C, Telouk P, Albarede F. A heavy metal baseline score predicts outcome in acute myeloid leukemia. Am J Hematol. 2020 04; 95(4):422-434. PMID: 31944361.
      Citations: 3     Fields:    Translation:Humans
    69. Bose P, Verstovsek S, Cortes JE, Tse S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Naqvi K, Short NJ, Masarova L, Villareal J, Pierce SA, Nogueras-Gonzalez G, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia. 2020 09; 34(9):2489-2492. PMID: 32099037.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    70. van Dijk AD, de Bont ESJM, Kornblau SM. Targeted therapy in acute myeloid leukemia: current status and new insights from a proteomic perspective. Expert Rev Proteomics. 2020 01; 17(1):1-10. PMID: 31945303.
      Citations: 5     Fields:    Translation:HumansAnimals
    71. Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HM. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol. 2019 Sep; 6(9):e480-e488. PMID: 31400961; PMCID: PMC6778960.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    72. Mahmud H, Ter Elst A, Scherpen FJG, Boer TM, Kampen KR, Guryev V, Peppelenbosch MM, Kornblau SM, de Bont ESJM, de Haas V. Peptide microarray of pediatric acute myeloid leukemia is related to relapse and reveals involvement of DNA damage response and repair. Oncotarget. 2019 Jul 23; 10(45):4679-4690. PMID: 31384395; PMCID: PMC6659796.
      Citations: 4     Fields:    
    73. Ruvolo PP, Hu CW, Qiu Y, Ruvolo VR, Go RL, Hubner SE, Coombes KR, Andreeff M, Qutub AA, Kornblau SM. LGALS3 is connected to CD74 in a previously unknown protein network that is associated with poor survival in patients with AML. EBioMedicine. 2019 Jun; 44:126-137. PMID: 31105032; PMCID: PMC6604360.
      Citations: 5     Fields:    Translation:HumansCells
    74. Mill CP, Fiskus W, DiNardo CD, Qian Y, Raina K, Rajapakshe K, Perera D, Coarfa C, Kadia TM, Khoury JD, Saenz DT, Saenz DN, Illendula A, Takahashi K, Kornblau SM, Green MR, Futreal AP, Bushweller JH, Crews CM, Bhalla KN. RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1. Blood. 2019 07 04; 134(1):59-73. PMID: 31023702; PMCID: PMC6609954.
      Citations: 29     Fields:    Translation:HumansAnimalsCells
    75. Hu CW, Qiu Y, Ligeralde A, Raybon AY, Yoo SY, Coombes KR, Qutub AA, Kornblau SM. A quantitative analysis of heterogeneities and hallmarks in acute myelogenous leukaemia. Nat Biomed Eng. 2019 11; 3(11):889-901. PMID: 30988472; PMCID: PMC7051028.
      Citations: 12     Fields:    Translation:HumansCells
    76. Hoff FW, Hu CW, Qutub AA, Qiu Y, Hornbaker MJ, Bueso-Ramos C, Abbas HA, Post SM, de Bont ESJM, Kornblau SM. Proteomic Profiling of Acute Promyelocytic Leukemia Identifies Two Protein Signatures Associated with Relapse. Proteomics Clin Appl. 2019 07; 13(4):e1800133. PMID: 30650251; PMCID: PMC6635093.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    77. Alfayez M, Wang SA, Bannon SA, Kontoyiannis DP, Kornblau SM, Orange JS, Mace EM, DiNardo CD. Myeloid malignancies with somatic GATA2 mutations can be associated with an immunodeficiency phenotype. Leuk Lymphoma. 2019 08; 60(8):2025-2033. PMID: 30648453.
      Citations: 9     Fields:    Translation:Humans
    78. Fiskus W, Cai T, DiNardo CD, Kornblau SM, Borthakur G, Kadia TM, Pemmaraju N, Bose P, Masarova L, Rajapakshe K, Perera D, Coarfa C, Mill CP, Saenz DT, Saenz DN, Sun B, Khoury JD, Shen Y, Konopleva M, Bhalla KN. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer J. 2019 01 15; 9(2):4. PMID: 30647404; PMCID: PMC6333829.
      Citations: 29     Fields:    Translation:HumansAnimalsCells
    79. Gu Z, Churchman ML, Roberts KG, Moore I, Zhou X, Nakitandwe J, Hagiwara K, Pelletier S, Gingras S, Berns H, Payne-Turner D, Hill A, Iacobucci I, Shi L, Pounds S, Cheng C, Pei D, Qu C, Newman S, Devidas M, Dai Y, Reshmi SC, Gastier-Foster J, Raetz EA, Borowitz MJ, Wood BL, Carroll WL, Zweidler-McKay PA, Rabin KR, Mattano LA, Maloney KW, Rambaldi A, Spinelli O, Radich JP, Minden MD, Rowe JM, Luger S, Litzow MR, Tallman MS, Racevskis J, Zhang Y, Bhatia R, Kohlschmidt J, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Evans WE, Jeha S, Pui CH, Yang J, Paietta E, Downing JR, Relling MV, Zhang J, Loh ML, Hunger SP, Mullighan CG, Mr?zek K. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet. 2019 02; 51(2):296-307. PMID: 30643249; PMCID: PMC6525306.
      Citations: 141     Fields:    Translation:HumansAnimalsCells
    80. Hoff FW, Lu Y, Kornblau SM. Antibody Screening. Adv Exp Med Biol. 2019; 1188:149-163. PMID: 31820387.
      Citations: 1     Fields:    
    81. Saenz DT, Fiskus W, Manshouri T, Mill CP, Qian Y, Raina K, Rajapakshe K, Coarfa C, Bose P, Borthakur G, Kadia TM, Khoury JD, Masarova L, Nowak AJ, Sun B, Saenz DN, Kornblau SM, Sharma S, Qiu P, Crews CM, Verstovsek S, Bhalla KN, Soldi R, Horrigan S. Targeting nuclear ?-catenin as therapy for post-myeloproliferative neoplasm secondary AML. Leukemia. 2019 06; 33(6):1373-1386. PMID: 30575820.
      Citations: 19     Fields:    Translation:HumansAnimalsCells
    82. Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver N, Ohanian M, Dinardo CD, Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi F. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol. 2019 Jan; 6(1):e29-e37. PMID: 30545576; PMCID: PMC6563344.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    83. Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, Ravandi F, Jabbour EJ, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Hidalgo Lopez J, Kornblau SM, Andreeff M, Flores W, Bueso-Ramos C, Blando J, Galera P, Calvo KR, Al-Atrash G, Allison JP, Kantarjian HM, Sharma P, Daver NG. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019 05 01; 125(9):1470-1481. PMID: 30500073; PMCID: PMC6467779.
      Citations: 84     Fields:    Translation:HumansCells
    84. Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, Dinardo CD, Montalban-Bravo G, Konopleva M, Alvarado Y, Bhalla KN, Fiskus W, Khouri M, Islam R, Kantarjian H, Garcia-Manero G. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Am J Hematol. 2019 01; 94(1):74-79. PMID: 30328139; PMCID: PMC6570401.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    85. Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia T, Nogueras-Gonzalez GM, Ning J, Pemmaraju N, DiNardo CD, Andreeff M, Pierce SA, Gordon T, Kornblau SM, Flores W, Alhamal Z, Bueso-Ramos C, Jorgensen JL, Patel KP, Blando J, Allison JP, Sharma P, Kantarjian H. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discov. 2019 03; 9(3):370-383. PMID: 30409776; PMCID: PMC6397669.
      Citations: 151     Fields:    Translation:HumansCTClinical Trials
    86. Foolad F, Gallegos C, Kornblau S, Kontoyiannis DP, De la Hoz A. Nivolumab-induced encephalitis post allogeneic stem cell transplant in a patient with Hodgkin's disease. Bone Marrow Transplant. 2019 05; 54(5):749-751. PMID: 30323308.
      Citations: 2     Fields:    Translation:Humans
    87. Assi R, Gur HD, Loghavi S, Konoplev SN, Konopleva M, Daver N, Tashakori M, Kadia T, Routbort M, Salem A, Kanagal-Shamanna R, Quesada A, Jabbour EJ, Kornblau SM, Medeiros LJ, Kantarjian H, Khoury JD. P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survival. Am J Hematol. 2018 11; 93(11):1376-1383. PMID: 30117185.
      Citations: 8     Fields:    Translation:HumansCells
    88. Brunetti L, Gundry MC, Sorcini D, Guzman AG, Huang YH, Ramabadran R, Gionfriddo I, Mezzasoma F, Milano F, Nabet B, Buckley DL, Kornblau SM, Lin CY, Sportoletti P, Martelli MP, Falini B, Goodell MA. Mutant NPM1 Maintains the Leukemic State through HOX Expression. Cancer Cell. 2018 09 10; 34(3):499-512.e9. PMID: 30205049; PMCID: PMC6159911.
      Citations: 77     Fields:    Translation:HumansAnimalsCells
    89. Hoff FW, Hu CW, Qutub AA, Qiu Y, Graver E, Hoang G, Chauhan M, de Bont ESJM, Kornblau SM. Mycoplasma contamination of leukemic cell lines alters protein expression determined by reverse phase protein arrays. Cytotechnology. 2018 Dec; 70(6):1529-1535. PMID: 30191439; PMCID: PMC6269355.
      Citations: 4     Fields:    
    90. Kampen KR, Scherpen FJG, Mahmud H, Ter Elst A, Guryev V, Verhagen HJMP, De Keersmaecker K, Smit L, Kornblau SM, De Bont ESJM, Mulder AB. VEGFC Antibody Therapy Drives Differentiation of AML. Cancer Res. 2018 10 15; 78(20):5940-5948. PMID: 30185550.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    91. Takahashi K, Wang F, Morita K, Yan Y, Hu P, Zhao P, Zhar AA, Wu CJ, Gumbs C, Little L, Tippen S, Thornton R, Coyle M, Mendoza M, Thompson E, Zhang J, DiNardo CD, Jain N, Ravandi F, Cortes JE, Garcia-Manero G, Kornblau S, Andreeff M, Jabbour E, Bueso-Ramos C, Takaori-Kondo A, Konopleva M, Patel K, Kantarjian H, Futreal PA. Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nat Commun. 2018 07 10; 9(1):2670. PMID: 29991687; PMCID: PMC6039465.
      Citations: 26     Fields:    Translation:HumansCells
    92. Hoff FW, Hu CW, Qutub AA, de Bont ESJM, Horton TM, Kornblau SM. Shining a light on cell signaling in leukemia through proteomics: relevance for the clinic. Expert Rev Proteomics. 2018 07; 15(7):613-622. PMID: 29898608; PMCID: PMC6444923.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    93. Yalniz FF, Daver N, Rezvani K, Kornblau S, Ohanian M, Borthakur G, DiNardo CD, Konopleva M, Burger J, Gasior Y, Pierce S, Kantarjian H, Garcia-Manero G. A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2018 10; 18(10):658-663.e2. PMID: 30001986; PMCID: PMC6750214.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    94. Chan LN, Chen Z, Braas D, Lee JW, Xiao G, Geng H, Cosgun KN, Hurtz C, Shojaee S, Cazzaniga V, Schjerven H, Kornblau SM, Konopleva M, Pufall MA, Liu GJ, Milne TA, Koeffler HP, Ross TS, Yamamoto KR, Dickins RA, Graeber TG, Ernst T, Hochhaus A, Cazzaniga G, S?nchez-Garc?a I, Borkhardt A, M?schen M. Author Correction: Metabolic gatekeeper function of B-lymphoid transcription factors. Nature. 2018 06; 558(7711):E5. PMID: 29849140.
      Citations:    Fields:    
    95. Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, Futreal A, Bhalla K, Zuo Z, Huh YO, Post SM, Ruvolo P, Garcia-Manero G, Andreeff M, Kornblau S, Borthakur G, Hu P, Medeiros LJ, Takahashi K, Hornbaker MJ, Zhang J, Huang X, Verstovsek S, Estrov Z, Pierce S, Ravandi F, Kantarjian HM, Bueso-Ramos CE, Cortes JE, Nogueras-Gonz?lez GM. MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma. 2019 01; 60(1):37-48. PMID: 29741984; PMCID: PMC6226369.
      Citations: 27     Fields:    Translation:Humans
    96. Wang M, Kornblau SM, Coombes KR. Decomposing the Apoptosis Pathway Into Biologically Interpretable Principal Components. Cancer Inform. 2018; 17:1176935118771082. PMID: 29881252; PMCID: PMC5987987.
      Citations: 9     
    97. Hoff FW, Hu CW, Qiu Y, Ligeralde A, Yoo SY, Mahmud H, de Bont ESJM, Qutub AA, Horton TM, Kornblau SM. Recognition of Recurrent Protein Expression Patterns in Pediatric Acute Myeloid Leukemia Identified New Therapeutic Targets. Mol Cancer Res. 2018 08; 16(8):1275-1286. PMID: 29669821; PMCID: PMC6512776.
      Citations: 7     Fields:    Translation:Humans
    98. Hoff FW, Hu CW, Qiu Y, Ligeralde A, Yoo SY, Scheurer ME, de Bont ESJM, Qutub AA, Kornblau SM, Horton TM. Recurrent Patterns of Protein Expression Signatures in Pediatric Acute Lymphoblastic Leukemia: Recognition and Therapeutic Guidance. Mol Cancer Res. 2018 08; 16(8):1263-1274. PMID: 29669823; PMCID: PMC6496939.
      Citations: 5     Fields:    Translation:Humans
    99. Li T, Liu Q, Garza N, Kornblau S, Jin VX. Integrative analysis reveals functional and regulatory roles of H3K79me2 in mediating alternative splicing. Genome Med. 2018 04 17; 10(1):30. PMID: 29665865; PMCID: PMC5902843.
      Citations: 12     Fields:    Translation:HumansCells
    100. Ruvolo PP, Ruvolo VR, Burks JK, Qiu Y, Wang RY, Shpall EJ, Mirandola L, Hail N, Zeng Z, McQueen T, Daver N, Post SM, Chiriva-Internati M, Kornblau SM, Andreeff M. Role of MSC-derived galectin 3 in the AML microenvironment. Biochim Biophys Acta Mol Cell Res. 2018 07; 1865(7):959-969. PMID: 29655803; PMCID: PMC5936474.
      Citations: 6     Fields:    Translation:HumansCells
    101. DiNardo CD, Routbort MJ, Bannon SA, Benton CB, Takahashi K, Kornblau SM, Luthra R, Kanagal-Shamanna R, Medeiros LJ, Garcia-Manero G, M Kantarjian H, Futreal PA, Meric-Bernstam F, Patel KP. Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels. Cancer. 2018 07 01; 124(13):2704-2713. PMID: 29682723.
      Citations: 11     Fields:    Translation:Humans
    102. van Dijk AD, Hu CW, de Bont ESJM, Qiu Y, Hoff FW, Yoo SY, Coombes KR, Qutub AA, Kornblau SM. Histone Modification Patterns Using RPPA-Based Profiling Predict Outcome in Acute Myeloid Leukemia Patients. Proteomics. 2018 04; 18(8):e1700379. PMID: 29505696.
      Citations: 4     Fields:    Translation:HumansCells
    103. Kornblau SM, Ruvolo PP, Wang RY, Battula VL, Shpall EJ, Ruvolo VR, McQueen T, Qui Y, Zeng Z, Pierce S, Jacamo R, Yoo SY, Le PM, Sun J, Hail N, Konopleva M, Andreeff M. Distinct protein signatures of acute myeloid leukemia bone marrow-derived stromal cells are prognostic for patient survival. Haematologica. 2018 05; 103(5):810-821. PMID: 29545342; PMCID: PMC5927978.
      Citations: 18     Fields:    Translation:HumansCells
    104. Jiang X, Mak PY, Mu H, Tao W, Mak DH, Kornblau S, Zhang Q, Ruvolo P, Burks JK, Zhang W, McQueen T, Pan R, Zhou H, Konopleva M, Cortes J, Liu Q, Andreeff M, Carter BZ. Disruption of Wnt/?-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia. Clin Cancer Res. 2018 05 15; 24(10):2417-2429. PMID: 29463558; PMCID: PMC5955840.
      Citations: 29     Fields:    Translation:HumansAnimalsCells
    105. Khan M, Carmona S, Sukhumalchandra P, Roszik J, Philips A, Perakis AA, Kerros C, Zhang M, Qiao N, John LSS, Zope M, Goldberg J, Qazilbash M, Jakher H, Clise-Dwyer K, Qiu Y, Mittendorf EA, Molldrem JJ, Kornblau SM, Alatrash G. Cathepsin G Is Expressed by Acute Lymphoblastic Leukemia and Is a Potential Immunotherapeutic Target. Front Immunol. 2017; 8:1975. PMID: 29422892; PMCID: PMC5790053.
      Citations: 9     Fields:    
    106. Kantarjian H, Ravandi F, Short NJ, Huang X, Jain N, Sasaki K, Daver N, Pemmaraju N, Khoury JD, Jorgensen J, Alvarado Y, Konopleva M, Garcia-Manero G, Kadia T, Yilmaz M, Bortakhur G, Burger J, Kornblau S, Wierda W, DiNardo C, Ferrajoli A, Jacob J, Garris R, O'Brien S, Jabbour E. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018 02; 19(2):240-248. PMID: 29352703.
      Citations: 58     Fields:    Translation:HumansCTClinical Trials
    107. Wang M, Abrams ZB, Kornblau SM, Coombes KR. Thresher: determining the number of clusters while removing outliers. BMC Bioinformatics. 2018 01 08; 19(1):9. PMID: 29310570; PMCID: PMC5759208.
      Citations: 10     Fields:    Translation:Humans
    108. Ngankeu A, Ranganathan P, Havelange V, Nicolet D, Volinia S, Powell BL, Kolitz JE, Uy GL, Stone RM, Kornblau SM, Andreeff M, Croce CM, Bloomfield CD, Garzon R. Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget. 2018 Jan 12; 9(4):4354-4365. PMID: 29435107; PMCID: PMC5796978.
      Citations: 7     Fields:    
    109. Post SM, Kornblau SM, Quint?s-Cardama A. p53 pathway dysfunction in AML: beyond TP53 mutations. Oncotarget. 2017 Dec 12; 8(65):108288-108289. PMID: 29312530; PMCID: PMC5752443.
      Citations: 3     Fields:    
    110. Abaza Y, M Kantarjian H, Faderl S, Jabbour E, Jain N, Thomas D, Kadia T, Borthakur G, D Khoury J, Burger J, Wierda W, O'Brien S, Konopleva M, Ferrajoli A, Kebriaei P, Dabaja B, Kornblau S, Alvarado Y, Daver N, Pemmaraju N, Bose P, Thompson P, Al Azzawi H, Kelly M, Garris R, Jain P, Garcia-Manero G, Cortes J, Ravandi F. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol. 2018 01; 93(1):91-99. PMID: 29047158.
      Citations: 21     Fields:    Translation:Humans
    111. Boddu P, Shah AR, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, Kadia T, Ravandi F, Jain N, Alhuraiji A, Burger J, Kornblau S, Pierce S, Dellasala S, Jabbour E, Kantarjian H, Cortes J. Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leuk Lymphoma. 2018 06; 59(6):1312-1322. PMID: 28972430; PMCID: PMC6120342.
      Citations: 4     Fields:    Translation:Humans
    112. Boddu P, Chen PL, Nagarajan P, Prieto VG, Won A, Chambers M, Kornblau S. Necrotizing fungal gingivitis in a patient with Acute Myelogenous Leukemia: visible yet obscure. J Oral Maxillofac Surg Med Pathol. 2018 Jan; 30(1):50-54. PMID: 29404266; PMCID: PMC5796543.
      Citations:    
    113. Boddu P, Kantarjian H, Borthakur G, Kadia T, Daver N, Pierce S, Andreeff M, Ravandi F, Cortes J, Kornblau SM. Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group. Blood Adv. 2017 Aug 22; 1(19):1546-1550. PMID: 29296796; PMCID: PMC5728474.
      Citations: 24     Fields:    
    114. Khan M, Cortes J, Kadia T, Naqvi K, Brandt M, Pierce S, Patel KP, Borthakur G, Ravandi F, Konopleva M, Kornblau S, Kantarjian H, Bhalla K, DiNardo CD. Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia. Int J Mol Sci. 2017 Jul 26; 18(8). PMID: 28933735; PMCID: PMC5578010.
      Citations: 11     Fields:    Translation:HumansCells
    115. Jacamo R, Davis RE, Ling X, Sonnylal S, Wang Z, Ma W, Zhang M, Ruvolo P, Ruvolo V, Wang RY, McQueen T, Lowe S, Zuber J, Kornblau SM, Konopleva M, Andreeff M. Tumor Trp53 status and genotype affect the bone marrow microenvironment in acute myeloid leukemia. Oncotarget. 2017 Oct 13; 8(48):83354-83369. PMID: 29137349; PMCID: PMC5663521.
      Citations: 4     Fields:    
    116. Zeng Z, Liu W, Tsao T, Qiu Y, Zhao Y, Samudio I, Sarbassov DD, Kornblau SM, Baggerly KA, Kantarjian HM, Konopleva M, Andreeff M. High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia. Haematologica. 2017 09; 102(9):1537-1548. PMID: 28659338; PMCID: PMC5685227.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    117. Katerndahl CDS, Heltemes-Harris LM, Willette MJL, Henzler CM, Frietze S, Yang R, Schjerven H, Silverstein KAT, Ramsey LB, Hubbard G, Wells AD, Scheijen B, van Leeuwen FN, Kornblau SM, Farrar MA, Kuiper RP, M?schen M. Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival. Nat Immunol. 2017 06; 18(6):694-704. PMID: 28369050; PMCID: PMC5540372.
      Citations: 35     Fields:    Translation:HumansAnimalsCells
    118. Carter BZ, Mak PY, Wang X, Yang H, Garcia-Manero G, Mak DH, Mu H, Ruvolo VR, Qiu Y, Coombes K, Zhang N, Ragon B, Weaver DT, Pachter JA, Kornblau S, Andreeff M. Focal Adhesion Kinase as a Potential Target in AML and MDS. Mol Cancer Ther. 2017 06; 16(6):1133-1144. PMID: 28270436; PMCID: PMC5457713.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    119. Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, Daver N, Takahashi K, DiNardo C, Jabbour E, Borthakur G, Konopleva M, Pierce S, Bueso-Ramos C, Patel K, Kornblau S, Kantarjian H, Young KH, Garcia-Manero G, Andreeff M. More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood. 2017 05 04; 129(18):2584-2587. PMID: 28246192; PMCID: PMC5418636.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    120. Chan LN, Chen Z, Braas D, Lee JW, Xiao G, Geng H, Cosgun KN, Hurtz C, Shojaee S, Cazzaniga V, Schjerven H, Kornblau SM, Konopleva M, Pufall MA, Liu GJ, Milne TA, Koeffler HP, Ross TS, Yamamoto KR, Dickins RA, Graeber TG, Ernst T, Hochhaus A, Cazzaniga G, S?nchez-Garc?a I, Borkhardt A, M?schen M. Metabolic gatekeeper function of B-lymphoid transcription factors. Nature. 2017 02 23; 542(7642):479-483. PMID: 28192788; PMCID: PMC5621518.
      Citations: 82     Fields:    Translation:HumansAnimalsCells
    121. Dinardo CD, Luskin MR, Carroll M, Smith C, Harrison J, Pierce S, Kornblau S, Konopleva M, Kadia T, Kantarjian H, Wertheim GB, Master SR. Validation of a clinical assay of multi-locus DNA methylation for prognosis of newly diagnosed AML. Am J Hematol. 2017 Feb; 92(2):E14-E15. PMID: 27804182; PMCID: PMC5915352.
      Citations: 5     Fields:    Translation:HumansCells
    122. Ishizawa J, Sugihara E, Kuninaka S, Mogushi K, Kojima K, Benton CB, Zhao R, Chachad D, Hashimoto N, Jacamo RO, Qiu Y, Yoo SY, Okamoto S, Andreeff M, Kornblau SM, Saya H. FZR1 loss increases sensitivity to DNA damage and consequently promotes murine and human B-cell acute leukemia. Blood. 2017 04 06; 129(14):1958-1968. PMID: 28143883; PMCID: PMC5383867.
      Citations: 8     Fields:    Translation:HumansAnimals
    123. Kelly AD, Kroeger H, Yamazaki J, Taby R, Neumann F, Yu S, Lee JT, Patel B, Li Y, He R, Liang S, Lu Y, Cesaroni M, Pierce SA, Kornblau SM, Bueso-Ramos CE, Ravandi F, Kantarjian HM, Jelinek J, Issa JP. A CpG island methylator phenotype in acute myeloid leukemia independent of IDH mutations and associated with a favorable outcome. Leukemia. 2017 10; 31(10):2011-2019. PMID: 28074068; PMCID: PMC5537054.
      Citations: 19     Fields:    Translation:HumansCells
    124. Schultz A, Mehta S, Hu CW, Hoff FW, Horton TM, Kornblau SM, Qutub AA. IDENTIFYING CANCER SPECIFIC METABOLIC SIGNATURES USING CONSTRAINT-BASED MODELS. Pac Symp Biocomput. 2017; 22:485-496. PMID: 27897000; PMCID: PMC5173378.
      Citations: 3     Fields:    Translation:HumansCells
    125. Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver N, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J, Ravandi F. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017 03 09; 129(10):1275-1283. PMID: 28003274; PMCID: PMC5413297.
      Citations: 73     Fields:    Translation:HumansCTClinical Trials
    126. Ragon BK, Kantarjian H, Jabbour E, Ravandi F, Cortes J, Borthakur G, DeBose L, Zeng Z, Schneider H, Pemmaraju N, Garcia-Manero G, Kornblau S, Wierda W, Burger J, DiNardo CD, Andreeff M, Konopleva M, Daver N. Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. Am J Hematol. 2017 Jan; 92(1):7-11. PMID: 27673440; PMCID: PMC5361214.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    127. Jain N, Roberts KG, Jabbour E, Patel K, Eterovic AK, Chen K, Zweidler-McKay P, Lu X, Fawcett G, Wang SA, Konoplev S, Harvey RC, Chen IM, Payne-Turner D, Valentine M, Thomas D, Garcia-Manero G, Ravandi F, Cortes J, Kornblau S, O'Brien S, Pierce S, Jorgensen J, Shaw KR, Willman CL, Mullighan CG, Kantarjian H, Konopleva M. Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. Blood. 2017 02 02; 129(5):572-581. PMID: 27919910; PMCID: PMC5290985.
      Citations: 95     Fields:    Translation:HumansCells
    128. Hu C, Qutub A, Qiu YH, Zhang X, Post SM, Zhang N, Coombes K, Kornblau SM, Quint?s-Cardama A. p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status. Leukemia. 2017 06; 31(6):1296-1305. PMID: 27885271.
      Citations: 39     Fields:    Translation:HumansCells
    129. Ding LW, Sun QY, Tan KT, Chien W, Mayakonda A, Yeoh AEJ, Kawamata N, Nagata Y, Xiao JF, Loh XY, Lin DC, Garg M, Jiang YY, Xu L, Lim SL, Liu LZ, Madan V, Sanada M, Hema Preethi SS, Lill M, Kantarjian HM, Kornblau SM, Miyano S, Liang DC, Ogawa S, Shih LY, Yang H, Koeffler HP, Fern?ndez LT. Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia. Cancer Res. 2017 01 15; 77(2):390-400. PMID: 27872090; PMCID: PMC5243866.
      Citations: 42     Fields:    Translation:HumansAnimals
    130. Gu Z, Churchman M, Roberts K, Li Y, Liu Y, Harvey RC, McCastlain K, Reshmi SC, Payne-Turner D, Iacobucci I, Shao Y, Chen IM, Valentine M, Pei D, Mungall KL, Mungall AJ, Ma Y, Moore R, Marra M, Stonerock E, Gastier-Foster JM, Devidas M, Dai Y, Wood B, Borowitz M, Larsen EE, Maloney K, Mattano LA, Angiolillo A, Salzer WL, Burke MJ, Gianni F, Spinelli O, Radich JP, Minden MD, Moorman AV, Patel B, Fielding AK, Rowe JM, Luger SM, Bhatia R, Aldoss I, Forman SJ, Kohlschmidt J, Marcucci G, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Paietta E, Willman CL, Loh ML, Hunger SP, Mullighan CG, Mr?zek K. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nat Commun. 2016 11 08; 7:13331. PMID: 27824051; PMCID: PMC5105166.
      Citations: 95     Fields:    Translation:HumansAnimalsCells
    131. Zhang J, McCastlain K, Yoshihara H, Xu B, Chang Y, Churchman ML, Wu G, Li Y, Wei L, Iacobucci I, Liu Y, Qu C, Wen J, Edmonson M, Payne-Turner D, Kaufmann KB, Takayanagi SI, Wienholds E, Ntziachristos P, Bakogianni S, Wang J, Aifantis I, Roberts KG, Ma J, Song G, Easton J, Mulder HL, Chen X, Newman S, Ma X, Rusch M, Gupta P, Boggs K, Vadodaria B, Dalton J, Liu Y, Valentine ML, Ding L, Lu C, Fulton RS, Fulton L, Tabib Y, Ochoa K, Devidas M, Pei D, Cheng C, Yang J, Evans WE, Relling MV, Pui CH, Jeha S, Harvey RC, Chen IL, Willman CL, Marcucci G, Bloomfield CD, Kohlschmidt J, Paietta E, Tallman MS, Stock W, Foster MC, Racevskis J, Rowe JM, Luger S, Kornblau SM, Shurtleff SA, Raimondi SC, Mardis ER, Wilson RK, Dick JE, Hunger SP, Loh ML, Downing JR, Mullighan CG, Waanders E, Mr?zek K, St. Jude Children's Research Hospital?Washington University Pediatric Cancer Genome Project. Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nat Genet. 2016 12; 48(12):1481-1489. PMID: 27776115; PMCID: PMC5144107.
      Citations: 107     Fields:    Translation:Humans
    132. Brown FC, Cifani P, Drill E, He J, Still E, Zhong S, Balasubramanian S, Pavlick D, Yilmazel B, Knapp KM, Alonzo TA, Meshinchi S, Stone RM, Kornblau SM, Marcucci G, Gamis AS, Byrd JC, Gonen M, Levine RL, Kentsis A. Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia. Br J Haematol. 2017 Jan; 176(1):86-91. PMID: 27766616; PMCID: PMC5177472.
      Citations: 18     Fields:    Translation:Humans
    133. Liu L, Chang Y, Yang T, Noren DP, Long B, Kornblau S, Qutub A, Ye J. Evolution-informed modeling improves outcome prediction for cancers. Evol Appl. 2017 Jan; 10(1):68-76. PMID: 28035236; PMCID: PMC5192825.
      Citations: 8     
    134. Butler JS, Qiu YH, Zhang N, Yoo SY, Coombes KR, Dent SY, Kornblau SM. Low expression of ASH2L protein correlates with a favorable outcome in acute myeloid leukemia. Leuk Lymphoma. 2017 05; 58(5):1207-1218. PMID: 28185526; PMCID: PMC5994918.
      Citations: 14     Fields:    Translation:HumansCells
    135. Madan V, Shyamsunder P, Han L, Mayakonda A, Nagata Y, Sundaresan J, Kanojia D, Yoshida K, Ganesan S, Hattori N, Fulton N, Tan KT, Alpermann T, Kuo MC, Rostami S, Matthews J, Sanada M, Liu LZ, Shiraishi Y, Miyano S, Chendamarai E, Hou HA, Malnassy G, Ma T, Garg M, Ding LW, Sun QY, Chien W, Ikezoe T, Lill M, Biondi A, Larson RA, Powell BL, Chng WJ, Tien HF, Heuser M, Ganser A, Koren-Michowitz M, Kornblau SM, Kantarjian HM, Nowak D, Hofmann WK, Yang H, Stock W, Ghavamzadeh A, Alimoghaddam K, Haferlach T, Ogawa S, Shih LY, Mathews V, Koeffler HP, L?bbert M. Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Leukemia. 2016 12; 30(12):2430. PMID: 27713533; PMCID: PMC7609306.
      Citations: 14     Fields:    
    136. Alatrash G, Garber HR, Zhang M, Sukhumalchandra P, Qiu Y, Jakher H, Perakis AA, Becker L, Yoo SY, Dwyer KC, Coombes K, Talukder AH, John LSS, Senyukov V, Lee DA, Sergeeva A, He H, Ma Q, Armistead PM, Roszik J, Mittendorf EA, Molldrem JJ, Hawke D, Lizee G, Kornblau SM. Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target. Leukemia. 2017 01; 31(1):234-237. PMID: 27573556; PMCID: PMC5215491.
      Citations: 13     Fields:    Translation:HumansAnimals
    137. Zeng Z, Wang RY, Qiu YH, Mak DH, Coombes K, Yoo SY, Zhang Q, Jessen K, Liu Y, Rommel C, Fruman DA, Kantarjian HM, Kornblau SM, Andreeff M, Konopleva M. MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells. Oncotarget. 2016 Aug 23; 7(34):55083-55097. PMID: 27391151; PMCID: PMC5342403.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    138. Dany M, Gencer S, Nganga R, Thomas RJ, Oleinik N, Baron KD, Szulc ZM, Ruvolo P, Kornblau S, Andreeff M, Ogretmen B. Targeting FLT3-ITD signaling mediates ceramide-dependent mitophagy and attenuates drug resistance in AML. Blood. 2016 10 13; 128(15):1944-1958. PMID: 27540013; PMCID: PMC5064718.
      Citations: 60     Fields:    Translation:HumansAnimalsCells
    139. Mahmud H, Kornblau SM, Ter Elst A, Scherpen FJ, Qiu YH, Coombes KR, de Bont ES. Epidermal growth factor receptor is expressed and active in a subset of acute myeloid leukemia. J Hematol Oncol. 2016 08 03; 9(1):64. PMID: 27488458; PMCID: PMC4971659.
      Citations: 11     Fields:    Translation:HumansCells
    140. Townsend EC, Murakami MA, Christodoulou A, Christie AL, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM, K?ster J, Jeay S. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183. PMID: 27479034.
      Citations: 26     Fields:    
    141. Rytting ME, Jabbour EJ, Jorgensen JL, Ravandi F, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Borthakur G, Garris R, Wang S, Pierce S, Schroeder K, Kornblau SM, Thomas DA, Cortes JE, O'Brien SM, Kantarjian HM. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-M?nster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Am J Hematol. 2016 08; 91(8):819-23. PMID: 27178680; PMCID: PMC5558853.
      Citations: 36     Fields:    Translation:HumansCells
    142. Noren DP, Long BL, Norel R, Rrhissorrakrai K, Hess K, Hu CW, Bisberg AJ, Schultz A, Engquist E, Liu L, Lin X, Chen GM, Xie H, Hunter GA, Boutros PC, Stepanov O, DREAM 9 AML-OPC Consortium, Norman T, Friend SH, Stolovitzky G, Kornblau S, Qutub AA. A Crowdsourcing Approach to Developing and Assessing Prediction Algorithms for AML Prognosis. PLoS Comput Biol. 2016 06; 12(6):e1004890. PMID: 27351836; PMCID: PMC4924788.
      Citations: 14     Fields:    Translation:Humans
    143. Rau RE, Rodriguez BA, Luo M, Jeong M, Rosen A, Rogers JH, Campbell CT, Daigle SR, Deng L, Song Y, Sweet S, Chevassut T, Andreeff M, Kornblau SM, Li W, Goodell MA. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. Blood. 2016 08 18; 128(7):971-81. PMID: 27335278; PMCID: PMC4990856.
      Citations: 57     Fields:    Translation:HumansAnimalsCells
    144. Sun QY, Ding LW, Tan KT, Chien W, Mayakonda A, Lin DC, Loh XY, Xiao JF, Meggendorfer M, Alpermann T, Garg M, Lim SL, Madan V, Hattori N, Nagata Y, Miyano S, Yeoh AE, Hou HA, Jiang YY, Takao S, Liu LZ, Tan SZ, Lill M, Hayashi M, Kinoshita A, Kantarjian HM, Kornblau SM, Ogawa S, Haferlach T, Yang H, Koeffler HP. Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD). Leukemia. 2017 01; 31(1):1-10. PMID: 27389053; PMCID: PMC5214979.
      Citations: 31     Fields:    Translation:HumansCells
    145. Piya S, Kornblau SM, Ruvolo VR, Mu H, Ruvolo PP, McQueen T, Davis RE, Hail N, Kantarjian H, Andreeff M, Borthakur G. Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia. Blood. 2016 09 01; 128(9):1260-9. PMID: 27268264; PMCID: PMC5009514.
      Citations: 43     Fields:    Translation:HumansAnimalsCells
    146. Eckstein OS, Wang L, Punia JN, Kornblau SM, Andreeff M, Wheeler DA, Goodell MA, Rau RE. Mixed-phenotype acute leukemia (MPAL) exhibits frequent mutations in DNMT3A and activated signaling genes. Exp Hematol. 2016 08; 44(8):740-4. PMID: 27208809; PMCID: PMC4956537.
      Citations: 17     Fields:    Translation:HumansCells
    147. DiNardo CD, Bannon SA, Routbort M, Franklin A, Mork M, Armanios M, Mace EM, Orange JS, Jeff-Eke M, Churpek JE, Takahashi K, Jorgensen JL, Garcia-Manero G, Kornblau S, Bertuch A, Cheung H, Bhalla K, Futreal A, Godley LA, Patel KP. Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC). Clin Lymphoma Myeloma Leuk. 2016 07; 16(7):417-428.e2. PMID: 27210295; PMCID: PMC4925265.
      Citations: 31     Fields:    Translation:Humans
    148. Carter BZ, Mak PY, Chen Y, Mak DH, Mu H, Jacamo R, Ruvolo V, Arold ST, Ladbury JE, Burks JK, Kornblau S, Andreeff M. Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NF?B/IL1? signaling network. Oncotarget. 2016 Apr 12; 7(15):20054-67. PMID: 26956049; PMCID: PMC4991438.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    149. Madan V, Shyamsunder P, Han L, Mayakonda A, Nagata Y, Sundaresan J, Kanojia D, Yoshida K, Ganesan S, Hattori N, Fulton N, Tan KT, Alpermann T, Kuo MC, Rostami S, Matthews J, Sanada M, Liu LZ, Shiraishi Y, Miyano S, Chendamarai E, Hou HA, Malnassy G, Ma T, Garg M, Ding LW, Sun QY, Chien W, Ikezoe T, Lill M, Biondi A, Larson RA, Powell BL, Chng WJ, Tien HF, Heuser M, Ganser A, Koren-Michowitz M, Kornblau SM, Kantarjian HM, Nowak D, Hofmann WK, Yang H, Stock W, Ghavamzadeh A, Alimoghaddam K, Haferlach T, Ogawa S, Shih LY, Mathews V, Koeffler HP, L?bbert M. Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Leukemia. 2016 08; 30(8):1672-81. PMID: 27063598; PMCID: PMC4972641.
      Citations: 36     Fields:    Translation:Humans
    150. Townsend EC, Murakami MA, Christodoulou A, Christie AL, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM, K?ster J, Garnache-Ottou F, Jeay S, Jeremias I, Tamburini J. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586. PMID: 27070704; PMCID: PMC5177991.
      Citations: 114     Fields:    Translation:HumansAnimalsCells
    151. Shojaee S, Chan LN, Buchner M, Cazzaniga V, Cosgun KN, Geng H, Qiu YH, Melnick A, Kornblau SM, Graeber TG, Wu H, Jumaa H, von Minden MD, Ernst T, Hochhaus A, Cazzaniga G, M?schen M. PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. Nat Med. 2016 Apr; 22(4):379-87. PMID: 26974310; PMCID: PMC5178869.
      Citations: 47     Fields:    Translation:HumansAnimalsCells
    152. Iacobucci I, Li Y, Roberts KG, Dobson SM, Kim JC, Payne-Turner D, Harvey RC, Valentine M, McCastlain K, Easton J, Yergeau D, Janke LJ, Shao Y, Chen IM, Rusch M, Zandi S, Kornblau SM, Konopleva M, Jabbour E, Paietta EM, Rowe JM, Pui CH, Gastier-Foster J, Gu Z, Reshmi S, Loh ML, Racevskis J, Tallman MS, Wiernik PH, Litzow MR, Willman CL, McPherson JD, Downing JR, Zhang J, Dick JE, Hunger SP, Mullighan CG. Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia. Cancer Cell. 2016 Feb 08; 29(2):186-200. PMID: 26859458; PMCID: PMC4750652.
      Citations: 60     Fields:    Translation:HumansCells
    153. Benito JM, Godfrey L, Kojima K, Hogdal L, Wunderlich M, Geng H, Marzo I, Harutyunyan KG, Golfman L, North P, Kerry J, Ballabio E, Gonzalo O, Qiu Y, Jeremias I, Debose L, O'Brien E, Ma H, Zhou P, Jacamo R, Park E, Coombes KR, Zhang N, Thomas DA, O'Brien S, Kantarjian HM, Leverson JD, Kornblau SM, Andreeff M, Zweidler-McKay PA, Mulloy JC, Letai A, Milne TA, Konopleva M, Chonghaile TN, M?schen M. MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. Cell Rep. 2015 Dec 29; 13(12):2715-27. PMID: 26711339; PMCID: PMC4700051.
      Citations: 55     Fields:    Translation:HumansAnimalsCells
    154. Nishida Y, Maeda A, Chachad D, Ishizawa J, Qiu YH, Kornblau SM, Kimura S, Andreeff M, Kojima K. Preclinical activity of the novel B-cell-specific Moloney murine leukemia virus integration site 1 inhibitor PTC-209 in acute myeloid leukemia: Implications for leukemia therapy. Cancer Sci. 2015 Dec; 106(12):1705-13. PMID: 26450753; PMCID: PMC4714665.
      Citations: 16     Fields:    Translation:HumansCells
    155. Yamazaki J, Taby R, Jelinek J, Raynal NJ, Cesaroni M, Pierce SA, Kornblau SM, Bueso-Ramos CE, Ravandi F, Kantarjian HM, Issa JP. Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia. J Natl Cancer Inst. 2015 Nov 13; 108(2). PMID: 26568194; PMCID: PMC4862435.
      Citations: 8     Fields:    Translation:HumansCells
    156. Garg M, Nagata Y, Kanojia D, Mayakonda A, Yoshida K, Haridas Keloth S, Zang ZJ, Okuno Y, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Ding LW, Alpermann T, Sun QY, Lin DC, Chien W, Madan V, Liu LZ, Tan KT, Sampath A, Venkatesan S, Inokuchi K, Wakita S, Yamaguchi H, Chng WJ, Kham SK, Yeoh AE, Sanada M, Schiller J, Kreuzer KA, Kornblau SM, Kantarjian HM, Haferlach T, Lill M, Kuo MC, Shih LY, Blau IW, Blau O, Yang H, Ogawa S, Koeffler HP. Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse. Blood. 2015 Nov 26; 126(22):2491-501. PMID: 26438511; PMCID: PMC4661172.
      Citations: 89     Fields:    Translation:HumansCells
    157. Gallardo M, Lee HJ, Zhang X, Bueso-Ramos C, Pageon LR, McArthur M, Multani A, Nazha A, Manshouri T, Parker-Thornburg J, Rapado I, Quintas-Cardama A, Kornblau SM, Martinez-Lopez J, Post SM. hnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic Malignancies. Cancer Cell. 2015 Oct 12; 28(4):486-499. PMID: 26412324; PMCID: PMC4652598.
      Citations: 66     Fields:    Translation:HumansAnimalsCells
    158. Jain P, Kantarjian H, Jabbour E, Gonzalez GN, Borthakur G, Pemmaraju N, Daver N, Gachimova E, Ferrajoli A, Kornblau S, Ravandi F, O'Brien S, Cortes J. Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. Lancet Haematol. 2015 Sep; 2(9):e376-83. PMID: 26436130; PMCID: PMC4587395.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    159. Hu CW, Kornblau SM, Slater JH, Qutub AA. Progeny Clustering: A Method to Identify Biological Phenotypes. Sci Rep. 2015 Aug 12; 5:12894. PMID: 26267476; PMCID: PMC4533525.
      Citations: 15     Fields:    Translation:HumansAnimals
    160. Ruvolo PP, Qiu Y, Coombes KR, Zhang N, Neeley ES, Ruvolo VR, Hail N, Borthakur G, Konopleva M, Andreeff M, Kornblau SM. Phosphorylation of GSK3a/? correlates with activation of AKT and is prognostic for poor overall survival in acute myeloid leukemia patients. BBA Clin. 2015 Dec; 4:59-68. PMID: 26674329; PMCID: PMC4661707.
      Citations: 19     
    161. Cheng X, Byrne M, Brown KD, Konopleva MY, Kornblau SM, Bennett RL, May WS. PKR inhibits the DNA damage response, and is associated with poor survival in AML and accelerated leukemia in NHD13 mice. Blood. 2015 Sep 24; 126(13):1585-94. PMID: 26202421; PMCID: PMC4582335.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    162. Takahashi K, Roh W, Zhang J, Propotopov A, Patel K, Strickland S, Kim A, Vnencak-Jones C, Pelletier S, Parmar S, Garcia-Manero G, Kornblau S, Chin L, Kantarjian H, Futreal PA, Ravandi F. Clonal evolution of acute myeloid leukemia relapsed after 19 years of remission. Am J Hematol. 2015 Jul; 90(7):E134-5. PMID: 25801490; PMCID: PMC4948743.
      Citations: 1     Fields:    Translation:HumansCells
    163. van der Sligte NE, Kampen KR, ter Elst A, Scherpen FJ, Meeuwsen-de Boer TG, Guryev V, van Leeuwen FN, Kornblau SM, de Bont ES. Essential role for cyclic-AMP responsive element binding protein 1 (CREB) in the survival of acute lymphoblastic leukemia. Oncotarget. 2015 Jun 20; 6(17):14970-81. PMID: 26008971; PMCID: PMC4558129.
      Citations: 15     Fields:    Translation:HumansCells
    164. Shojaee S, Caeser R, Buchner M, Park E, Swaminathan S, Hurtz C, Geng H, Chan LN, Klemm L, Qiu YH, Zhang N, Coombes KR, Paietta E, Molkentin J, Koeffler HP, Willman CL, Hunger SP, Melnick A, Kornblau SM, Hofmann WK, M?schen M. Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. Cancer Cell. 2015 Jul 13; 28(1):114-28. PMID: 26073130; PMCID: PMC4565502.
      Citations: 54     Fields:    Translation:HumansAnimalsCells
    165. Cole A, Wang Z, Coyaud E, Voisin V, Gronda M, Jitkova Y, Mattson R, Hurren R, Babovic S, Maclean N, Restall I, Wang X, Jeyaraju DV, Sukhai MA, Prabha S, Bashir S, Ramakrishnan A, Leung E, Qia YH, Zhang N, Combes KR, Ketela T, Lin F, Houry WA, Aman A, Al-Awar R, Zheng W, Wienholds E, Xu CJ, Dick J, Wang JC, Moffat J, Minden MD, Eaves CJ, Bader GD, Hao Z, Kornblau SM, Raught B, Schimmer AD. Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia. Cancer Cell. 2015 Jun 08; 27(6):864-76. PMID: 26058080; PMCID: PMC4461837.
      Citations: 123     Fields:    Translation:HumansAnimals
    166. Kampen KR, Scherpen FJ, Garcia-Manero G, Yang H, Kaspers GJ, Cloos J, Zwaan CM, van den Heuvel-Eibrink MM, Kornblau SM, De Bont ES. EphB1 Suppression in Acute Myelogenous Leukemia: Regulating the DNA Damage Control System. Mol Cancer Res. 2015 Jun; 13(6):982-92. PMID: 25944917; PMCID: PMC4983719.
      Citations: 9     Fields:    Translation:HumansCells
    167. Geng H, Hurtz C, Chen Z, Baumjohann D, Chen WY, LaTocha D, Ballabio E, Xiao G, Lee JW, Deucher A, Qi Z, Park E, Huang C, Nahar R, Kweon SM, Shojaee S, Chan LN, Yu J, Kornblau SM, Ye BH, Ansel KM, Paietta E, Melnick A, Tyner JW, Loh ML, Roeder RG, Druker BJ, Burger JA, Milne TA, Lenz KB, Thompson S, Goloviznina NA, Huan J, Bijl JJ, Hunger SP, Kurre P, Chang BH, M?schen M. Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. Cancer Cell. 2015 Mar 09; 27(3):409-25. PMID: 25759025; PMCID: PMC4618684.
      Citations: 59     Fields:    Translation:HumansCells
    168. Konopleva M, Thall PF, Yi CA, Borthakur G, Coveler A, Bueso-Ramos C, Benito J, Konoplev S, Gu Y, Ravandi F, Jabbour E, Faderl S, Thomas D, Cortes J, Kadia T, Kornblau S, Daver N, Pemmaraju N, Nguyen HQ, Feliu J, Lu H, Wei C, Wilson WR, Melink TJ, Gutheil JC, Andreeff M, Estey EH, Kantarjian H. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica. 2015 Jul; 100(7):927-34. PMID: 25682597; PMCID: PMC4486227.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    169. Hamdi A, Cao K, Poon LM, Aung F, Kornblau S, Fernandez Vina MA, Champlin RE, Ciurea SO. Are changes in HLA Ags responsible for leukemia relapse after HLA-matched allogeneic hematopoietic SCT? Bone Marrow Transplant. 2015 Mar; 50(3):411-3. PMID: 25621795; PMCID: PMC4807113.
      Citations: 10     Fields:    Translation:Humans
    170. Han L, Qiu P, Zeng Z, Jorgensen JL, Mak DH, Burks JK, Schober W, McQueen TJ, Cortes J, Tanner SD, Roboz GJ, Kantarjian HM, Kornblau SM, Guzman ML, Andreeff M, Konopleva M. Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. Cytometry A. 2015 Apr; 87(4):346-56. PMID: 25598437; PMCID: PMC4388314.
      Citations: 51     Fields:    Translation:HumansCells
    171. McGee SF, Kornblau SM, Qiu Y, Look AT, Zhang N, Yoo SY, Coombes KR, Kentsis A. Biological properties of ligand-dependent activation of the MET receptor kinase in acute myeloid leukemia. Leukemia. 2015 May; 29(5):1218-21. PMID: 25541150; PMCID: PMC4638218.
      Citations: 4     Fields:    Translation:HumansCells
    172. Perez-Andreu V, Roberts KG, Xu H, Smith C, Zhang H, Yang W, Harvey RC, Payne-Turner D, Devidas M, Cheng IM, Carroll WL, Heerema NA, Carroll AJ, Raetz EA, Gastier-Foster JM, Marcucci G, Bloomfield CD, Kohlschmidt J, Stock W, Kornblau SM, Konopleva M, Paietta E, Rowe JM, Luger SM, Tallman MS, Dean M, Burchard EG, Torgerson DG, Yue F, Wang Y, Pui CH, Jeha S, Relling MV, Evans WE, Gerhard DS, Loh ML, Willman CL, Hunger SP, Mullighan CG, Yang JJ, Mr?zek K. A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood. 2015 Jan 22; 125(4):680-6. PMID: 25468567; PMCID: PMC4304112.
      Citations: 53     Fields:    Translation:HumansCells
    173. Oancea C, Brill B, Roos J, Heinssmann M, Bug G, Mian AA, Guillen NA, Kornblau SM, Henschler R, Ruthardt M, R?ster B. STAT activation status differentiates leukemogenic from non-leukemogenic stem cells in AML and is suppressed by arsenic in t(6;9)-positive AML. Genes Cancer. 2014 Nov; 5(11-12):378-92. PMID: 25568664; PMCID: PMC4279436.
      Citations: 3     
    174. Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, McCastlain K, Ding L, Lu C, Song G, Ma J, Becksfort J, Rusch M, Chen SC, Easton J, Cheng J, Boggs K, Santiago-Morales N, Iacobucci I, Fulton RS, Wen J, Valentine M, Cheng C, Paugh SW, Devidas M, Chen IM, Reshmi S, Smith A, Hedlund E, Gupta P, Nagahawatte P, Wu G, Chen X, Yergeau D, Vadodaria B, Mulder H, Winick NJ, Larsen EC, Carroll WL, Heerema NA, Carroll AJ, Grayson G, Tasian SK, Moore AS, Keller F, Frei-Jones M, Whitlock JA, Raetz EA, White DL, Hughes TP, Guidry Auvil JM, Smith MA, Marcucci G, Bloomfield CD, Kohlschmidt J, Stock W, Kornblau SM, Konopleva M, Paietta E, Pui CH, Jeha S, Relling MV, Evans WE, Gerhard DS, Gastier-Foster JM, Mardis E, Wilson RK, Loh ML, Downing JR, Hunger SP, Willman CL, Zhang J, Mullighan CG, Mr?zek K. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014 Sep 11; 371(11):1005-15. PMID: 25207766; PMCID: PMC4191900.
      Citations: 506     Fields:    Translation:HumansAnimalsCells
    175. Zabriskie MS, Eide CA, Tantravahi SK, Estrada J, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, Stenke L, Barbany G, Lange T, Ossenkoppele GJ, Press RD, Chuah C, Goldberg SL, Wetzler M, Friedman R, Deininger M, Reynolds KR, Heaton WL, Eiring AM, Pomicter AD, Khorashad JS, Kelley TW, Druker BJ, Deininger MW, O'Hare T, Vellore NA, Nicolini FE, Hern?ndez-Boluda JC, Mahon FX, Etienne G, Baccarani M, Soverini S, Rosti G, Rousselot P, Baron R. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014 Sep 08; 26(3):428-442. PMID: 25132497; PMCID: PMC4160372.
      Citations: 131     Fields:    Translation:HumansCells
    176. Zhang N, Qiu YH, Post S, Creighton CJ, Cortes J, Coombes KR, Kornblau SM, Quint?s-Cardama A. Loss of TRIM62 expression is an independent adverse prognostic factor in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Feb; 15(2):115-127.e15. PMID: 25248926; PMCID: PMC4560255.
      Citations: 18     Fields:    Translation:Humans
    177. Mak PY, Mak DH, Ruvolo V, Jacamo R, Kornblau SM, Kantarjian H, Andreeff M, Carter BZ. Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signalling in acute myeloid leukaemia. Br J Haematol. 2014 Nov; 167(3):376-84. PMID: 25079338; PMCID: PMC4357400.
      Citations: 15     Fields:    Translation:HumansCells
    178. Rytting ME, Thomas DA, O'Brien SM, Ravandi-Kashani F, Jabbour EJ, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Cortes JE, Borthakur G, Garris R, Cardenas-Turanzas M, Schroeder K, Jorgensen JL, Kornblau SM, Kantarjian HM. Augmented Berlin-Frankfurt-M?nster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer. 2014 Dec 01; 120(23):3660-8. PMID: 25042398; PMCID: PMC4239168.
      Citations: 29     Fields:    Translation:Humans
    179. Ruvolo PP, Ruvolo VR, Jacamo R, Burks JK, Zeng Z, Duvvuri SR, Zhou L, Qiu Y, Coombes KR, Zhang N, Yoo SY, Pan R, Hail N, Konopleva M, Calin G, Kornblau SM, Andreeff M. The protein phosphatase 2A regulatory subunit B55a is a modulator of signaling and microRNA expression in acute myeloid leukemia cells. Biochim Biophys Acta. 2014 Sep; 1843(9):1969-77. PMID: 24858343; PMCID: PMC4165504.
      Citations: 21     Fields:    Translation:HumansCells
    180. Mak PY, Mak DH, Mu H, Shi Y, Ruvolo P, Ruvolo V, Jacamo R, Burks JK, Wei W, Huang X, Kornblau SM, Andreeff M, Carter BZ. Apoptosis repressor with caspase recruitment domain is regulated by MAPK/PI3K and confers drug resistance and survival advantage to AML. Apoptosis. 2014 Apr; 19(4):698-707. PMID: 24337870; PMCID: PMC3943601.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    181. Havelange V, Ranganathan P, Geyer S, Nicolet D, Huang X, Yu X, Volinia S, Kornblau SM, Andreeff M, Croce CM, Marcucci G, Bloomfield CD, Garzon R. Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML. Blood. 2014 Apr 10; 123(15):2412-5. PMID: 24596420; PMCID: PMC3983615.
      Citations: 29     Fields:    Translation:Humans
    182. Konopleva MY, Walter RB, Faderl SH, Jabbour EJ, Zeng Z, Borthakur G, Huang X, Kadia TM, Ruvolo PP, Feliu JB, Lu H, Debose L, Burger JA, Andreeff M, Liu W, Baggerly KA, Kornblau SM, Doyle LA, Estey EH, Kantarjian HM. Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia. Clin Cancer Res. 2014 Apr 15; 20(8):2226-35. PMID: 24583795; PMCID: PMC3989412.
      Citations: 37     Fields:    Translation:HumansCellsCTClinical Trials
    183. Carter BZ, Mak PY, Mak DH, Shi Y, Qiu Y, Bogenberger JM, Mu H, Tibes R, Yao H, Coombes KR, Jacamo RO, McQueen T, Kornblau SM, Andreeff M. Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents. J Natl Cancer Inst. 2014 Feb; 106(2):djt440. PMID: 24526787; PMCID: PMC3952202.
      Citations: 31     Fields:    Translation:HumansCells
    184. Bogenberger JM, Kornblau SM, Pierceall WE, Lena R, Chow D, Shi CX, Mantei J, Ahmann G, Gonzales IM, Choudhary A, Valdez R, Camoriano J, Fauble V, Tiedemann RE, Qiu YH, Coombes KR, Cardone M, Braggio E, Yin H, Azorsa DO, Mesa RA, Stewart AK, Tibes R. BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia. 2014 Aug; 28(8):1657-65. PMID: 24451410; PMCID: PMC4131248.
      Citations: 74     Fields:    Translation:HumansCells
    185. Bansal H, Yihua Q, Iyer SP, Ganapathy S, Proia DA, Proia D, Penalva LO, Uren PJ, Suresh U, Carew JS, Karnad AB, Weitman S, Tomlinson GE, Rao MK, Kornblau SM, Bansal S. WTAP is a novel oncogenic protein in acute myeloid leukemia. Leukemia. 2014 May; 28(5):1171-4. PMID: 24413322; PMCID: PMC4369791.
      Citations: 119     Fields:    Translation:Humans
    186. Karjalainen K, Pasqualini R, Cortes JE, Kornblau SM, Lichtiger B, O'Brien S, Kantarjian HM, Sidman RL, Arap W, Koivunen E. Design, development, and validation of a high-throughput drug-screening assay for targeting of human leukemia. Cancer. 2014 Feb 15; 120(4):589-602. PMID: 24496871; PMCID: PMC4457455.
      Citations:    Fields:    Translation:Humans
    187. Kornblau SM, Qutub A, Yao H, York H, Qiu YH, Graber D, Ravandi F, Cortes J, Andreeff M, Zhang N, Coombes KR. Proteomic profiling identifies distinct protein patterns in acute myelogenous leukemia CD34+CD38- stem-like cells. PLoS One. 2013; 8(10):e78453. PMID: 24223100; PMCID: PMC3816767.
      Citations: 22     Fields:    Translation:HumansCells
    188. Pierceall WE, Kornblau SM, Carlson NE, Huang X, Blake N, Lena R, Elashoff M, Konopleva M, Cardone MH, Andreeff M. BH3 profiling discriminates response to cytarabine-based treatment of acute myelogenous leukemia. Mol Cancer Ther. 2013 Dec; 12(12):2940-9. PMID: 24092807; PMCID: PMC3881173.
      Citations: 19     Fields:    Translation:Humans
    189. Kornblau SM, Cohen AC, Soper D, Huang YW, Cesano A. Age-related changes of healthy bone marrow cell signaling in response to growth factors provide insight into low risk MDS. Cytometry B Clin Cytom. 2014 Nov; 86(6):383-96. PMID: 24106013; PMCID: PMC4922007.
      Citations: 3     Fields:    Translation:HumansCells
    190. Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients =60 years with newly diagnosed acute myeloid leukemia. Am J Hematol. 2013 Nov; 88(11):961-6. PMID: 23877926; PMCID: PMC4110914.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    191. Kornblau SM, Cohen AC, Soper D, Huang YW, Cesano A. Age-related changes of healthy bone marrow cell signaling in response to growth factors provide insight into low risk MDS. Cytometry B Clin Cytom. 2013 Aug 20. PMID: 23959783.
      Citations: 2     Fields:    
    192. Irwin ME, Nelson LD, Santiago-O'Farrill JM, Knouse PD, Miller CP, Palla SL, Siwak DR, Mills GB, Estrov Z, Li S, Kornblau SM, Hughes DP, Chandra J. Small molecule ErbB inhibitors decrease proliferative signaling and promote apoptosis in philadelphia chromosome-positive acute lymphoblastic leukemia. PLoS One. 2013; 8(8):e70608. PMID: 23936456; PMCID: PMC3731286.
      Citations: 13     Fields:    Translation:HumansCells
    193. Strati P, Keating MJ, Wierda WG, Badoux XC, Calin S, Reuben JM, O'Brien S, Kornblau SM, Kantarjian HM, Gao H, Ferrajoli A. Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia. Blood. 2013 Aug 01; 122(5):734-7. PMID: 23801633; PMCID: PMC4123325.
      Citations: 24     Fields:    Translation:HumansCellsCTClinical Trials
    194. Pierce A, Whetton AD, Meyer S, Ravandi-Kashani F, Borthakur G, Coombes KR, Zhang N, Kornblau S. Transglutaminase 2 expression in acute myeloid leukemia: association with adhesion molecule expression and leukemic blast motility. Proteomics. 2013 Jul; 13(14):2216-2224. PMID: 23576428; PMCID: PMC4959038.
      Citations: 13     Fields:    Translation:HumansCells
    195. Daver N, Vega-Ruiz A, Kantarjian HM, Estrov Z, Ferrajoli A, Kornblau S, Verstovsek S, Garcia-Manero G, Cortes JE. A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome. Eur J Cancer Care (Engl). 2013 Sep; 22(5):605-11. PMID: 23701251; PMCID: PMC3745781.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    196. Cancer Genome Atlas Research Network, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A, Hoadley K, Triche TJ, Laird PW, Baty JD, Fulton LL, Fulton R, Heath SE, Kalicki-Veizer J, Kandoth C, Klco JM, Koboldt DC, Kanchi KL, Kulkarni S, Lamprecht TL, Larson DE, Lin L, Lu C, McLellan MD, McMichael JF, Payton J, Schmidt H, Spencer DH, Tomasson MH, Wallis JW, Wartman LD, Watson MA, Welch J, Wendl MC, Ally A, Balasundaram M, Birol I, Butterfield Y, Chiu R, Chu A, Chuah E, Chun HJ, Corbett R, Dhalla N, Guin R, He A, Hirst C, Hirst M, Holt RA, Jones S, Karsan A, Lee D, Li HI, Marra MA, Mayo M, Moore RA, Mungall K, Parker J, Pleasance E, Plettner P, Schein J, Stoll D, Swanson L, Tam A, Thiessen N, Varhol R, Wye N, Zhao Y, Gabriel S, Getz G, Sougnez C, Zou L, Leiserson MD, Vandin F, Wu HT, Applebaum F, Baylin SB, Akbani R, Broom BM, Chen K, Motter TC, Nguyen K, Weinstein JN, Zhang N, Ferguson ML, Adams C, Black A, Bowen J, Gastier-Foster J, Grossman T, Lichtenberg T, Wise L, Davidsen T, Demchok JA, Shaw KR, Sheth M, Sofia HJ, Yang L, Downing JR, Eley G. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013 05 30; 368(22):2059-74. PMID: 23634996; PMCID: PMC3767041.
      Citations: 2081     Fields:    Translation:HumansCells
    197. Kojima K, Kornblau SM, Ruvolo V, Dilip A, Duvvuri S, Davis RE, Zhang M, Wang Z, Coombes KR, Zhang N, Qiu YH, Burks JK, Kantarjian H, Shacham S, Kauffman M, Andreeff M. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood. 2013 May 16; 121(20):4166-74. PMID: 23564911; PMCID: PMC3656451.
      Citations: 112     Fields:    Translation:HumansCells
    198. Kannan S, Sutphin RM, Hall MG, Golfman LS, Fang W, Nolo RM, Akers LJ, Hammitt RA, McMurray JS, Kornblau SM, Melnick AM, Figueroa ME, Zweidler-McKay PA. Notch activation inhibits AML growth and survival: a potential therapeutic approach. J Exp Med. 2013 Feb 11; 210(2):321-37. PMID: 23359069; PMCID: PMC3570106.
      Citations: 74     Fields:    Translation:HumansAnimalsCells
    199. Yamazaki J, Estecio MR, Lu Y, Long H, Malouf GG, Graber D, Huo Y, Ramagli L, Liang S, Kornblau SM, Jelinek J, Issa JP. The epigenome of AML stem and progenitor cells. Epigenetics. 2013 Jan; 8(1):92-104. PMID: 23249680; PMCID: PMC3549884.
      Citations: 21     Fields:    Translation:HumansCells
    200. Gruber TA, Larson Gedman A, Zhang J, Koss CS, Marada S, Ta HQ, Chen SC, Su X, Ogden SK, Dang J, Wu G, Gupta V, Andersson AK, Pounds S, Shi L, Easton J, Barbato MI, Mulder HL, Manne J, Wang J, Rusch M, Ranade S, Ganti R, Parker M, Ma J, Radtke I, Ding L, Cazzaniga G, Biondi A, Kornblau SM, Ravandi F, Kantarjian H, Nimer SD, Ley TJ, Ballerini P, Shurtleff S, Tomizawa D, Adachi S, Hayashi Y, Tawa A, Shih LY, Liang DC, Rubnitz JE, Pui CH, Mardis ER, Wilson RK, Downing JR, D?hner K, D?hner H. An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. Cancer Cell. 2012 Nov 13; 22(5):683-97. PMID: 23153540; PMCID: PMC3547667.
      Citations: 97     Fields:    Translation:HumansAnimalsCells
    201. Tsao T, Shi Y, Kornblau S, Lu H, Konoplev S, Antony A, Ruvolo V, Qiu YH, Zhang N, Coombes KR, Andreeff M, Kojima K, Konopleva M. Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells. Ann Hematol. 2012 Dec; 91(12):1861-70. PMID: 22893484; PMCID: PMC3750747.
      Citations: 53     Fields:    Translation:HumansAnimalsCells
    202. Frolova O, Samudio I, Benito JM, Jacamo R, Kornblau SM, Markovic A, Schober W, Lu H, Qiu YH, Buglio D, McQueen T, Pierce S, Shpall E, Konoplev S, Thomas D, Kantarjian H, Lock R, Andreeff M, Konopleva M. Regulation of HIF-1a signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment. Cancer Biol Ther. 2012 Aug; 13(10):858-70. PMID: 22785211; PMCID: PMC3414410.
      Citations: 50     Fields:    Translation:HumansAnimalsCells
    203. Zeng Z, Shi YX, Tsao T, Qiu Y, Kornblau SM, Baggerly KA, Liu W, Jessen K, Liu Y, Kantarjian H, Rommel C, Fruman DA, Andreeff M, Konopleva M. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. Blood. 2012 Sep 27; 120(13):2679-89. PMID: 22826565; PMCID: PMC3460689.
      Citations: 62     Fields:    Translation:HumansAnimalsCells
    204. Ozpolat B, Akar U, Tekedereli I, Alpay SN, Barria M, Gezgen B, Zhang N, Coombes K, Kornblau S, Lopez-Berestein G. PKCd Regulates Translation Initiation through PKR and eIF2a in Response to Retinoic Acid in Acute Myeloid Leukemia Cells. Leuk Res Treatment. 2012; 2012:482905. PMID: 23259068; PMCID: PMC3505929.
      Citations: 4     
    205. Konoplev S, Yin CC, Kornblau SM, Kantarjian HM, Konopleva M, Andreeff M, Lu G, Zuo Z, Luthra R, Medeiros LJ, Bueso-Ramos CE. Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia. Leuk Lymphoma. 2013 Jan; 54(1):138-44. PMID: 22691121; PMCID: PMC3925981.
      Citations: 31     Fields:    Translation:HumansCells
    206. York H, Kornblau SM, Qutub AA. Network analysis of reverse phase protein expression data: characterizing protein signatures in acute myeloid leukemia cytogenetic categories t(8;21) and inv(16). Proteomics. 2012 Jul; 12(13):2084-93. PMID: 22623292; PMCID: PMC4376995.
      Citations: 8     Fields:    Translation:HumansCells
    207. Carter BZ, Qiu Y, Huang X, Diao L, Zhang N, Coombes KR, Mak DH, Konopleva M, Cortes J, Kantarjian HM, Mills GB, Andreeff M, Kornblau SM. Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. Blood. 2012 Jul 05; 120(1):173-80. PMID: 22645176; PMCID: PMC3390955.
      Citations: 49     Fields:    Translation:HumansCells
    208. Kadia TM, Kantarjian H, Kornblau S, Borthakur G, Faderl S, Freireich EJ, Luthra R, Garcia-Manero G, Pierce S, Cortes J, Ravandi F. Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS. Cancer. 2012 Nov 15; 118(22):5550-9. PMID: 22569880; PMCID: PMC3416961.
      Citations: 19     Fields:    Translation:HumansCells
    209. Qiu YH, Post SM, Zhang Y, Creighton CJ, Cortes J, Kornblau SM, Quint?s-Cardama A. Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34-positive compartment. Cancer. 2012 Nov 01; 118(21):5283-92. PMID: 22517119; PMCID: PMC3435477.
      Citations: 13     Fields:    Translation:HumansCells
    210. Neeley ES, Baggerly KA, Kornblau SM. Surface Adjustment of Reverse Phase Protein Arrays using Positive Control Spots. Cancer Inform. 2012; 11:77-86. PMID: 22550399; PMCID: PMC3329188.
      Citations: 28     
    211. Lee DW, Futami M, Carroll M, Feng Y, Wang Z, Fernandez M, Whichard Z, Chen Y, Kornblau S, Shpall EJ, Bueso-Ramos CE, Corey SJ. Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is associated with miR-210 and miR-155. Oncogene. 2012 Sep 13; 31(37):4085-94. PMID: 22249254.
      Citations: 22     Fields:    Translation:HumansCells
    212. Ravandi F, Patel K, Luthra R, Faderl S, Konopleva M, Kadia T, Brandt M, Pierce S, Kornblau S, Andreeff M, Wang X, Garcia-Manero G, Cortes J, Kantarjian H. Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. Cancer. 2012 May 15; 118(10):2665-73. PMID: 22020636; PMCID: PMC4060157.
      Citations: 22     Fields:    Translation:Humans
    213. Kornblau SM, Qiu YH, Zhang N, Singh N, Faderl S, Ferrajoli A, York H, Qutub AA, Coombes KR, Watson DK. Abnormal expression of FLI1 protein is an adverse prognostic factor in acute myeloid leukemia. Blood. 2011 Nov 17; 118(20):5604-12. PMID: 21917756; PMCID: PMC3217360.
      Citations: 29     Fields:    Translation:Humans
    214. Badoux XC, Keating MJ, Wen S, Lee BN, Sivina M, Reuben J, Wierda WG, O'Brien SM, Faderl S, Kornblau SM, Burger JA, Ferrajoli A. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood. 2011 Sep 29; 118(13):3489-98. PMID: 21725050; PMCID: PMC4123422.
      Citations: 61     Fields:    Translation:HumansCellsCTClinical Trials
    215. Ruvolo PP, Qui YH, Coombes KR, Zhang N, Ruvolo VR, Borthakur G, Konopleva M, Andreeff M, Kornblau SM. Low expression of PP2A regulatory subunit B55a is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients. Leukemia. 2011 Nov; 25(11):1711-7. PMID: 21660042; PMCID: PMC3191228.
      Citations: 41     Fields:    Translation:HumansCells
    216. Ruvolo PP, Zhou L, Watt JC, Ruvolo VR, Burks JK, Jiffar T, Kornblau S, Konopleva M, Andreeff M. Targeting PKC-mediated signal transduction pathways using enzastaurin to promote apoptosis in acute myeloid leukemia-derived cell lines and blast cells. J Cell Biochem. 2011 Jun; 112(6):1696-707. PMID: 21360576; PMCID: PMC3394435.
      Citations: 23     Fields:    Translation:HumansCells
    217. Heltemes-Harris LM, Willette MJ, Ramsey LB, Qiu YH, Neeley ES, Zhang N, Thomas DA, Koeuth T, Baechler EC, Kornblau SM, Farrar MA. Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia. J Exp Med. 2011 Jun 06; 208(6):1135-49. PMID: 21606506; PMCID: PMC3173246.
      Citations: 74     Fields:    Translation:HumansAnimalsCells
    218. Starkova J, Gadgil S, Qiu YH, Zhang N, Hermanova I, Kornblau SM, Drabkin HA. Up-regulation of homeodomain genes, DLX1 and DLX2, by FLT3 signaling. Haematologica. 2011 Jun; 96(6):820-8. PMID: 21357706; PMCID: PMC3105643.
      Citations: 12     Fields:    Translation:HumansCells
    219. Alousi A, Ghosh S, Rice D, Moran C, Manning JT, Iliescu C, Hymes S, Kim S, Bashoura L, Kornblau S, Dickey BF. Pleuropericarditis, obliterative bronchiolitis and lymphocytic interstitial pneumonitis after allogeneic haematopoietic stem cell transplantation. BMJ Case Rep. 2011 Feb 23; 2011. PMID: 22707568; PMCID: PMC3062890.
      Citations: 1     Fields:    Translation:HumansCells
    220. Kornblau SM, Covey T, Putta S, Cohen A, Woronicz J, Fantl WJ, Gayko U, Cesano A. Signaling changes in the stem cell factor-AKT-S6 pathway in diagnostic AML samples are associated with disease relapse. Blood Cancer J. 2011 Feb; 1(2):e3. PMID: 22829109; PMCID: PMC3255271.
      Citations: 2     Fields:    
    221. Hunsucker SA, Magarotto V, Kuhn DJ, Kornblau SM, Wang M, Weber DM, Thomas SK, Shah JJ, Voorhees PM, Xie H, Cornfeld M, Nemeth JA, Orlowski RZ. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol. 2011 Mar; 152(5):579-92. PMID: 21241278; PMCID: PMC3402914.
      Citations: 29     Fields:    Translation:HumansCells
    222. Kornblau SM, Coombes KR. Use of reverse phase protein microarrays to study protein expression in leukemia: technical and methodological lessons learned. Methods Mol Biol. 2011; 785:141-55. PMID: 21901598; PMCID: PMC4554538.
      Citations: 15     Fields:    Translation:Humans
    223. Telesca D, Kornblau SM, Suchard MA, Ji Y, M?ller P. Modeling Protein Expression and Protein Signaling Pathways. J Am Stat Assoc. 2011; 107(500):1372-1384. PMID: 26246646; PMCID: PMC4523312.
      Citations: 8     
    224. Bjorklund CC, Ma W, Wang ZQ, Davis RE, Kuhn DJ, Kornblau SM, Wang M, Shah JJ, Orlowski RZ. Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem. 2011 Apr 01; 286(13):11009-20. PMID: 21189262; PMCID: PMC3064156.
      Citations: 63     Fields:    Translation:HumansCells
    225. Yang L, Wang H, Kornblau SM, Graber DA, Zhang N, Matthews JA, Wang M, Weber DM, Thomas SK, Shah JJ, Zhang L, Lu G, Zhao M, Muddasani R, Yoo SY, Baggerly KA, Orlowski RZ. Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma. Oncogene. 2011 Mar 17; 30(11):1329-40. PMID: 21057542; PMCID: PMC4128235.
      Citations: 23     Fields:    Translation:HumansCells
    226. Carter BZ, Qiu YH, Zhang N, Coombes KR, Mak DH, Thomas DA, Ravandi F, Kantarjian HM, Koller E, Andreeff M, Kornblau SM. Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML. Blood. 2011 Jan 20; 117(3):780-7. PMID: 21041716; PMCID: PMC3035072.
      Citations: 27     Fields:    Translation:HumansCells
    227. Rosen DB, Minden MD, Kornblau SM, Cohen A, Gayko U, Putta S, Woronicz J, Evensen E, Fantl WJ, Cesano A. Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP). PLoS One. 2010 Oct 27; 5(10):e13543. PMID: 21048955; PMCID: PMC2965086.
      Citations: 14     Fields:    Translation:HumansCells
    228. Ma W, Wang M, Wang ZQ, Sun L, Graber D, Matthews J, Champlin R, Yi Q, Orlowski RZ, Kwak LW, Weber DM, Thomas SK, Shah J, Kornblau S, Davis RE. Effect of long-term storage in TRIzol on microarray-based gene expression profiling. Cancer Epidemiol Biomarkers Prev. 2010 Oct; 19(10):2445-52. PMID: 20805315; PMCID: PMC2966770.
      Citations: 26     Fields:    Translation:HumansCells
    229. Kornblau SM, McCue D, Singh N, Chen W, Estrov Z, Coombes KR. Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood. 2010 Nov 18; 116(20):4251-61. PMID: 20679526; PMCID: PMC4081283.
      Citations: 65     Fields:    Translation:Humans
    230. Kornblau SM, Minden MD, Rosen DB, Putta S, Cohen A, Covey T, Spellmeyer DC, Fantl WJ, Gayko U, Cesano A. Dynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapy. Clin Cancer Res. 2010 Jul 15; 16(14):3721-33. PMID: 20525753; PMCID: PMC3385931.
      Citations: 38     Fields:    Translation:HumansCells
    231. Tsao T, Kornblau S, Safe S, Watt JC, Ruvolo V, Chen W, Qiu Y, Coombes KR, Ju Z, Abdelrahim M, Schober W, Ling X, Kardassis D, Meyer C, Schimmer A, Kantarjian H, Andreeff M, Konopleva M. Role of peroxisome proliferator-activated receptor-gamma and its coactivator DRIP205 in cellular responses to CDDO (RTA-401) in acute myelogenous leukemia. Cancer Res. 2010 Jun 15; 70(12):4949-60. PMID: 20501850; PMCID: PMC3727426.
      Citations: 22     Fields:    Translation:HumansCellsCTClinical Trials
    232. Kornblau SM, Singh N, Qiu Y, Chen W, Zhang N, Coombes KR. Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia. Clin Cancer Res. 2010 Mar 15; 16(6):1865-74. PMID: 20215543; PMCID: PMC3385949.
      Citations: 58     Fields:    Translation:HumansCells
    233. Guerrouahen BS, Futami M, Vaklavas C, Kanerva J, Whichard ZL, Nwawka K, Blanchard EG, Lee FY, Robinson LJ, Arceci R, Kornblau SM, Wieder E, Cayre YE, Corey SJ. Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias. Clin Cancer Res. 2010 Feb 15; 16(4):1149-58. PMID: 20145167; PMCID: PMC2988651.
      Citations: 21     Fields:    Translation:HumansCells
    234. Kornblau SM, Minden MD, Hogge D, Cohen A, Cesano A. Insights into acute myeloid leukemia via single cell network profiling. Clin Lab Int. 2010 Feb-Mar; 34(1):12-15. PMID: 26726291; PMCID: PMC4696776.
      Citations:    
    235. Levin VA, Panchabhai SC, Shen L, Kornblau SM, Qiu Y, Baggerly KA. Different changes in protein and phosphoprotein levels result from serum starvation of high-grade glioma and adenocarcinoma cell lines. J Proteome Res. 2010 Jan; 9(1):179-91. PMID: 19894763; PMCID: PMC3386607.
      Citations: 31     Fields:    Translation:HumansCells
    236. Garzon R, Heaphy CE, Havelange V, Fabbri M, Volinia S, Tsao T, Zanesi N, Kornblau SM, Marcucci G, Calin GA, Andreeff M, Croce CM. MicroRNA 29b functions in acute myeloid leukemia. Blood. 2009 Dec 17; 114(26):5331-41. PMID: 19850741; PMCID: PMC2796138.
      Citations: 213     Fields:    Translation:HumansAnimals
    237. Dotti G, Tian M, Savoldo B, Najjar A, Cooper LJ, Jackson J, Smith A, Mawlawi O, Uthamanthil R, Borne A, Brammer D, Paolillo V, Alauddin M, Gonzalez C, Steiner D, Decker WK, Marini F, Kornblau S, Bollard CM, Shpall EJ, Gelovani JG. Repetitive noninvasive monitoring of HSV1-tk-expressing T cells intravenously infused into nonhuman primates using positron emission tomography and computed tomography with 18F-FEAU. Mol Imaging. 2009 Jul-Aug; 8(4):230-7. PMID: 19728977; PMCID: PMC3178066.
      Citations: 15     Fields:    Translation:AnimalsCells
    238. Poland KS, Shardy DL, Azim M, Naeem R, Krance RA, Dreyer ZE, Neeley ES, Zhang N, Qiu YH, Kornblau SM, Plon SE. Overexpression of ZNF342 by juxtaposition with MPO promoter/enhancer in the novel translocation t(17;19)(q23;q13.32) in pediatric acute myeloid leukemia and analysis of ZNF342 expression in leukemia. Genes Chromosomes Cancer. 2009 Jun; 48(6):480-9. PMID: 19255975; PMCID: PMC3385932.
      Citations: 4     Fields:    Translation:HumansCells
    239. Kantarjian H, Ravandi F, O'Brien S, Thomas D, Vidal-Senmache G, Wierda W, Kornblau S, Cortes J, Quint?s-Cardama A. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer. 2009 Jun 01; 115(11):2482-90. PMID: 19280591; PMCID: PMC4180711.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    240. Heinrichs S, Kulkarni RV, Bueso-Ramos CE, Levine RL, Loh ML, Li C, Neuberg D, Kornblau SM, Issa JP, Gilliland DG, Garcia-Manero G, Kantarjian HM, Estey EH, Look AT. Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia. 2009 Sep; 23(9):1605-13. PMID: 19387468; PMCID: PMC2950785.
      Citations: 30     Fields:    Translation:Humans
    241. Kantarjian H, Jones D, Shan J, Borthakur G, Thomas D, Kornblau S, O'Brien S, Cortes J, Quint?s-Cardama A. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood. 2009 Jun 18; 113(25):6315-21. PMID: 19369233; PMCID: PMC3953080.
      Citations: 66     Fields:    Translation:HumansCells
    242. Neeley ES, Kornblau SM, Coombes KR, Baggerly KA. Variable slope normalization of reverse phase protein arrays. Bioinformatics. 2009 Jun 01; 25(11):1384-9. PMID: 19336447; PMCID: PMC3968550.
      Citations: 55     Fields:    
    243. Kornblau SM, Tibes R, Qiu YH, Chen W, Kantarjian HM, Andreeff M, Coombes KR, Mills GB. Functional proteomic profiling of AML predicts response and survival. Blood. 2009 Jan 01; 113(1):154-64. PMID: 18840713; PMCID: PMC2951831.
      Citations: 132     Fields:    Translation:HumansCells
    244. Andreeff M, Ruvolo V, Gadgil S, Zeng C, Coombes K, Chen W, Kornblau S, Drabkin HA, Bar?n AE. HOX expression patterns identify a common signature for favorable AML. Leukemia. 2008 Nov; 22(11):2041-7. PMID: 18668134; PMCID: PMC2676170.
      Citations: 57     Fields:    Translation:HumansCells
    245. Tong W, Kantarjian H, Thomas D, Ravandi F, Kornblau S, Manshouri T, Cortes JE, Garcia-Manero G, Verstovsek S, Quint?s-Cardama A. A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia. 2008 May; 22(5):965-70. PMID: 18385750; PMCID: PMC4369783.
      Citations: 42     Fields:    Translation:HumansCellsCTClinical Trials
    246. Valdez BC, Murray D, Ramdas L, de Lima M, Jones R, Kornblau S, Betancourt D, Li Y, Champlin RE, Andersson BS. Altered gene expression in busulfan-resistant human myeloid leukemia. Leuk Res. 2008 Nov; 32(11):1684-97. PMID: 18339423; PMCID: PMC2633244.
      Citations: 26     Fields:    Translation:HumansCells
    247. Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F, Fabbri M, Coombes K, Alder H, Nakamura T, Flomenberg N, Marcucci G, Calin GA, Kornblau SM, Kantarjian H, Bloomfield CD, Andreeff M, Croce CM. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood. 2008 Mar 15; 111(6):3183-9. PMID: 18187662; PMCID: PMC2265455.
      Citations: 285     Fields:    Translation:HumansCells
    248. Tibes R, Kornblau SM, Qiu Y, Mousses SM, Robbins C, Moses T, Carpten JD. PI3K/AKT pathway activation in acute myeloid leukaemias is not associated with AKT1 pleckstrin homology domain mutation. Br J Haematol. 2008 Feb; 140(3):344-7. PMID: 18053070; PMCID: PMC3385948.
      Citations: 17     Fields:    Translation:HumansCells
    249. Lennon PA, Abruzzo LV, Medeiros LJ, Cromwell C, Zhang X, Yin CC, Kornblau SM, Konopieva M, Lin P. Aberrant EVI1 expression in acute myeloid leukemias associated with the t(3;8)(q26;q24). Cancer Genet Cytogenet. 2007 Aug; 177(1):37-42. PMID: 17693189.
      Citations: 7     Fields:    Translation:HumansCells
    250. Ozdemir E, Saliba RM, Champlin RE, Couriel DR, Giralt SA, de Lima M, Khouri IF, Hosing C, Kornblau SM, Anderlini P, Shpall EJ, Qazilbash MH, Molldrem JJ, Chemaly RF, Komanduri KV. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant. 2007 Jul; 40(2):125-36. PMID: 17530009.
      Citations: 40     Fields:    Translation:HumansCells
    251. Kornblau SM, Aycox PG, Stephens C, McCue LD, Champlin RE, Marini FC. Control of graft-versus-host disease with maintenance of the graft-versus-leukemia effect in a murine allogeneic transplant model using retrovirally transduced murine suicidal lymphocytes. Exp Hematol. 2007 May; 35(5):842-53. PMID: 17577932; PMCID: PMC4075062.
      Citations: 5     Fields:    Translation:AnimalsCells
    252. Aribi A, Kantarjian HM, Estey EH, Koller CA, Thomas DA, Kornblau SM, Faderl SH, Laddie NM, Garcia-Manero G, Cortes JE. Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer. 2007 Apr 01; 109(7):1355-9. PMID: 17326049.
      Citations: 25     Fields:    Translation:Humans
    253. Kornblau SM, Banker DE, Stirewalt D, Shen D, Lemker E, Verstovsek S, Estrov Z, Faderl S, Cortes J, Beran M, Jackson CE, Chen W, Estey E, Appelbaum FR. Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. Blood. 2007 Apr 01; 109(7):2999-3006. PMID: 17158228; PMCID: PMC1852228.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    254. Sun K, Li M, Konopleva M, Konoplev S, Stephens LC, Kornblau SM, Frolova O, Wilkins DE, Ma W, Welniak LA, Andreeff M, Murphy WJ. The synthetic triterpenoid, CDDO, suppresses alloreactive T cell responses and reduces murine early acute graft-versus-host disease mortality. Biol Blood Marrow Transplant. 2007 May; 13(5):521-9. PMID: 17448911; PMCID: PMC4559277.
      Citations: 7     Fields:    Translation:AnimalsCells
    255. Giles FJ, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Thomas D, Wierda W, Ferrajoli A, Kornblau S, Pierce S, Albitar M, Cortes J, Kantarjian H. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol. 2007 Feb; 136(4):624-7. PMID: 17223919.
      Citations: 90     Fields:    Translation:Humans
    256. Ozpolat B, Akar U, Steiner M, Zorrilla-Calancha I, Tirado-Gomez M, Colburn N, Danilenko M, Kornblau S, Berestein GL. Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells. Mol Cancer Res. 2007 Jan; 5(1):95-108. PMID: 17259349.
      Citations: 34     Fields:    Translation:HumansCells
    257. Kornblau SM, Qiu YH, Bekele BN, Cade JS, Zhou X, Harris D, Jackson CE, Estrov Z, Andreeff M. Studying the right cell in acute myelogenous leukemia: dynamic changes of apoptosis and signal transduction pathway protein expression in chemotherapy resistant ex-vivo selected "survivor cells". Cell Cycle. 2006 Dec; 5(23):2769-77. PMID: 17172852.
      Citations: 7     Fields:    Translation:HumansCells
    258. Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, Mills GB, Kornblau SM. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther. 2006 Oct; 5(10):2512-21. PMID: 17041095.
      Citations: 400     Fields:    Translation:HumansCells
    259. Giles F, Verstovsek S, Garcia-Manero G, Thomas D, Ravandi F, Wierda W, Ferrajoli A, Kornblau S, Jabbour E, Shan J, O'brien S, Albitar M, Kantarjian H. Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse. Br J Haematol. 2006 Jul; 134(1):58-60. PMID: 16803568.
      Citations: 6     Fields:    Translation:Humans
    260. Kornblau SM, Womble M, Qiu YH, Jackson CE, Chen W, Konopleva M, Estey EH, Andreeff M. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood. 2006 Oct 01; 108(7):2358-65. PMID: 16763210; PMCID: PMC1895551.
      Citations: 110     Fields:    Translation:HumansCells
    261. Kurinna S, Konopleva M, Palla SL, Chen W, Kornblau S, Contractor R, Deng X, May WS, Andreeff M, Ruvolo PP. Bcl2 phosphorylation and active PKC alpha are associated with poor survival in AML. Leukemia. 2006 Jul; 20(7):1316-9. PMID: 16642043.
      Citations: 18     Fields:    Translation:HumansCells
    262. Zeng Z, Samudio IJ, Zhang W, Estrov Z, Harris D, Frolova O, Hail N, Chen W, Kornblau SM, Huang P, Lu Y, Mills GB, Andreeff M, Konopleva M, Pelicano H. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res. 2006 Apr 01; 66(7):3737-46. PMID: 16585200.
      Citations: 42     Fields:    Translation:HumansAnimalsCells
    263. Giles F, Verstovsek S, Thomas D, Gerson S, Cortes J, Faderl S, Ferrajoli A, Ravandi F, Kornblau S, Garcia-Manero G, Jabbour E, O'Brien S, Karsten V, Cahill A, Yee K, Albitar M, Sznol M, Kantarjian H. Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia. Clin Cancer Res. 2005 Nov 01; 11(21):7817-24. PMID: 16278404.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    264. Yee KW, Hagey A, Verstovsek S, Cortes J, Garcia-Manero G, O'Brien SM, Faderl S, Thomas D, Wierda W, Kornblau S, Ferrajoli A, Albitar M, McKeegan E, Grimm DR, Mueller T, Holley-Shanks RR, Sahelijo L, Gordon GB, Kantarjian HM, Giles FJ. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2005 Sep 15; 11(18):6615-24. PMID: 16166440.
      Citations: 17     Fields:    Translation:HumansCellsCTClinical Trials
    265. Kornblau SM, Womble M, Cade JS, Lemker E, Qiu YH. Comparative analysis of the effects of sample source and test methodology on the assessment of protein expression in acute myelogenous leukemia. Leukemia. 2005 Sep; 19(9):1550-7. PMID: 15973452.
      Citations: 6     Fields:    Translation:HumansCells
    266. Heinrichs S, Berman JN, Ortiz TM, Kornblau SM, Neuberg DS, Estey EH, Look AT. CD34+ cell selection is required to assess HOXA9 expression levels in patients with myelodysplastic syndrome. Br J Haematol. 2005 Jul; 130(1):83-6. PMID: 15982348.
      Citations: 8     Fields:    Translation:HumansCells
    267. Giles FJ, Kantarjian HM, Cortes JE, Faderl S, Verstovsek S, Thomas D, Garcia-Manero G, Wierda W, Ferrajoli A, Kornblau S, Mattiuzzi GN, Tsimberidou AM, Albitar M, O'Brien SM, Estey E. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. Leuk Res. 2005 Jun; 29(6):649-52. PMID: 15863204.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    268. Milella M, Precupanu CM, Gregorj C, Ricciardi MR, Petrucci MT, Kornblau SM, Tafuri A, Andreeff M. Beyond single pathway inhibition: MEK inhibitors as a platform for the development of pharmacological combinations with synergistic anti-leukemic effects. Curr Pharm Des. 2005; 11(21):2779-95. PMID: 16101455.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    269. Konopleva M, Elstner E, McQueen TJ, Tsao T, Sudarikov A, Hu W, Schober WD, Wang RY, Chism D, Kornblau SM, Younes A, Collins SJ, Koeffler HP, Andreeff M. Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias. Mol Cancer Ther. 2004 Oct; 3(10):1249-62. PMID: 15486192.
      Citations: 44     Fields:    Translation:HumansCells
    270. Benson AB, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA, McCallum R, Mitchell EP, O'Dorisio TM, Vokes EE, Wadler S. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004 Jul 15; 22(14):2918-26. PMID: 15254061.
      Citations: 171     Fields:    Translation:Humans
    271. Andreeff M, Milella M, Carter BZ, Tabe Y, Ricciardi MR, Sneed T, Ruvolo P, Contractor R, Tsao T, Schober W, Evans R, McQueen T, Zeng Z, Kornblau SM, McCubrey J, Estey E, Mills GB, Reed JC, Konopleva M. Targeted therapy of AML new concepts. Ann Hematol. 2004; 83 Suppl 1:S51-3. PMID: 15124670.
      Citations: 5     Fields:    Translation:HumansCells
    272. Kantarjian H, O'Brien S, Cortes J, Giles F, Shan J, Rios MB, Faderl S, Verstovsek S, Garcia-Manero G, Wierda W, Kornblau S, Ferrajoli A, Keating M, Talpaz M. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 1):68-75. PMID: 14734453.
      Citations: 12     Fields:    Translation:Humans
    273. Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM, Garcia-Manero G, Keating MJ, Andreeff M, Jeha S, Beran M, Verstovsek S, Pierce S, Letvak L, Salvado A, Champlin R, Talpaz M, Kantarjian H. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004 Jun 15; 103(12):4396-407. PMID: 14551133.
      Citations: 172     Fields:    Translation:HumansCTClinical Trials
    274. O'Brien S, Giles F, Talpaz M, Cortes J, Rios MB, Shan J, Thomas D, Andreeff M, Kornblau S, Faderl S, Garcia-Manero G, White K, Mallard S, Freireich E, Kantarjian HM. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer. 2003 Sep 01; 98(5):888-93. PMID: 12942553.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    275. Carter BZ, Kornblau SM, Tsao T, Wang RY, Schober WD, Milella M, Sung HG, Reed JC, Andreeff M. Caspase-independent cell death in AML: caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosis. Blood. 2003 Dec 01; 102(12):4179-86. PMID: 12920030.
      Citations: 35     Fields:    Translation:HumansCells
    276. Kantarjian H, O'Brien S, Cortes J, Giles F, Thomas D, Kornblau S, Shan J, Beth Rios M, Keating M, Freireich E, Talpaz M. Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications. Cancer. 2003 Jul 01; 98(1):81-5. PMID: 12833459.
      Citations: 13     Fields:    Translation:Humans
    277. Milella M, Kornblau SM, Andreeff M. The mitogen-activated protein kinase signaling module as a therapeutic target in hematologic malignancies. Rev Clin Exp Hematol. 2003 Jun; 7(2):160-90. PMID: 14763161.
      Citations: 11     Fields:    Translation:HumansCells
    278. Kantarjian H, Talpaz M, O'Brien S, Giles F, Rios MB, White K, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Kornblau S, Cortes J. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 2003 May 01; 97(9):2225-8. PMID: 12712475.
      Citations: 4     Fields:    Translation:Humans
    279. Bonini C, Grez M, Traversari C, Ciceri F, Marktel S, Ferrari G, Dinauer M, Sadat M, Aiuti A, Deola S, Radrizzani M, Hagenbeek A, Apperley J, Ebeling S, Martens A, Kolb HJ, Weber M, Lotti F, Grande A, Weissinger E, Bueren JA, Lamana M, Falkenburg JH, Heemskerk MH, Austin T, Kornblau S, Marini F, Benati C, Magnani Z, Cazzaniga S, Toma S, Gallo-Stampino C, Introna M, Slavin S, Greenberg PD, Bregni M, Mavilio F, Bordignon C. Safety of retroviral gene marking with a truncated NGF receptor. Nat Med. 2003 Apr; 9(4):367-9. PMID: 12669036.
      Citations: 63     Fields:    Translation:HumansAnimalsCells
    280. Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S, Thomas DA, Garcia-Manero G, Issa JP, Andreeff M, Kornblau SM, Koller C, Beran M, Keating M, Rios MB, Shan J, Resta D, Capdeville R, Hayes K, Albitar M, Freireich EJ, Cortes JE. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res. 2002 Jul; 8(7):2177-87. PMID: 12114418.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    281. Kantarjian HM, O'Brien S, Cortes JE, Smith TL, Rios MB, Shan J, Yang Y, Giles FJ, Thomas DA, Faderl S, Garcia-Manero G, Jeha S, Wierda W, Issa JP, Kornblau SM, Keating M, Resta D, Capdeville R, Talpaz M. Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res. 2002 Jul; 8(7):2167-76. PMID: 12114417.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    282. Garcia-Manero G, Daniel J, Smith TL, Kornblau SM, Lee MS, Kantarjian HM, Issa JP. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res. 2002 Jul; 8(7):2217-24. PMID: 12114423.
      Citations: 44     Fields:    Translation:HumansCells
    283. Milella M, Estrov Z, Kornblau SM, Carter BZ, Konopleva M, Tari A, Schober WD, Harris D, Leysath CE, Lopez-Berestein G, Huang Z, Andreeff M. Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood. 2002 May 01; 99(9):3461-4. PMID: 11964319.
      Citations: 31     Fields:    Translation:HumansCells
    284. O'Brien S, Talpaz M, Cortes J, Shan J, Giles FJ, Faderl S, Thomas D, Garcia-Manero G, Mallard S, Beth M, Koller C, Kornblau S, Andreeff M, Murgo A, Keating M, Kantarjian HM. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer. 2002 Apr 01; 94(7):2024-32. PMID: 11932905.
      Citations: 11     Fields:    Translation:Humans
    285. Milella M, Kornblau SM, Estrov Z, Carter BZ, Lapillonne H, Harris D, Konopleva M, Zhao S, Estey E, Andreeff M. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest. 2001 Sep; 108(6):851-9. PMID: 11560954; PMCID: PMC200930.
      Citations: 106     Fields:    Translation:HumansCells
    286. Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, David CL, Phan AT, Colburn DE, Rashid A, Estey EH. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 2001 Jul 15; 92(2):406-13. PMID: 11466696.
      Citations: 51     Fields:    Translation:Humans
    287. Champlin R, Khouri I, Anderlini P, Gajewski J, Kornblau S, Molldrem J, Shimoni A, Ueno N, Giralt S. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Bone Marrow Transplant. 2001 May; 27 Suppl 2:S13-22. PMID: 11436116.
      Citations: 6     Fields:    Translation:Humans
    288. Kornblau SM, Stiouf I, Snell V, Przepiorka D, Stephens LC, Champlin R, Marini FC. Preemptive control of graft-versus-host disease in a murine allogeneic transplant model using retrovirally transduced murine suicidal lymphocytes. Cancer Res. 2001 Apr 15; 61(8):3355-60. PMID: 11309292.
      Citations: 5     Fields:    Translation:AnimalsCells
    289. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C, Claxton D, Donato M, Bruton J, Cohen A, Davis M, Andersson BS, Anderlini P, Gajewski J, Kornblau S, Andreeff M, Przepiorka D, Ueno NT, Molldrem J, Champlin R. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001 Feb 01; 97(3):631-7. PMID: 11157478.
      Citations: 104     Fields:    Translation:HumansCTClinical Trials
    290. Deng X, Kornblau SM, Ruvolo PP, May WS. Regulation of Bcl2 phosphorylation and potential significance for leukemic cell chemoresistance. J Natl Cancer Inst Monogr. 2001; (28):30-7. PMID: 11158204.
      Citations: 30     Fields:    Translation:HumansCells
    291. Sarriera JE, Albitar M, Estrov Z, Gidel C, Aboul-Nasr R, Manshouri T, Kornblau S, Chang KS, Kantarjian H, Estey E. Comparison of outcome in acute myelogenous leukemia patients with translocation (8;21) found by standard cytogenetic analysis and patients with AML1/ETO fusion transcript found only by PCR testing. Leukemia. 2001 Jan; 15(1):57-61. PMID: 11243400.
      Citations: 7     Fields:    Translation:HumansCells
    292. Giles F, Cortes J, Garcia-Manero G, Kornblau S, Estey E, Kwari M, Murgo A, Kantarjian H. Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia. Invest New Drugs. 2001; 19(1):13-20. PMID: 11291829.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    293. Faderl S, Kantarjian HM, Estey E, Manshouri T, Chan CY, Rahman Elsaied A, Kornblau SM, Cortes J, Thomas DA, Pierce S, Keating MJ, Estrov Z, Albitar M. The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia. Cancer. 2000 Nov 01; 89(9):1976-82. PMID: 11064355.
      Citations: 34     Fields:    Translation:Humans
    294. Champlin R, Khouri I, Shimoni A, Gajewski J, Kornblau S, Molldrem J, Ueno N, Giralt S, Anderlini P. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol. 2000 Oct; 111(1):18-29. PMID: 11091179.
      Citations: 28     Fields:    Translation:HumansCells
    295. Tamm I, Kornblau SM, Segall H, Krajewski S, Welsh K, Kitada S, Scudiero DA, Tudor G, Qui YH, Monks A, Andreeff M, Reed JC. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res. 2000 May; 6(5):1796-803. PMID: 10815900.
      Citations: 199     Fields:    Translation:HumansCells
    296. Kornblau SM, Vu HT, Ruvolo P, Estrov Z, O'Brien S, Cortes J, Kantarjian H, Andreeff M, May WS. BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia. Clin Cancer Res. 2000 Apr; 6(4):1401-9. PMID: 10778970.
      Citations: 16     Fields:    Translation:HumansCells
    297. Kornblau S, Benson AB, Catalano R, Champlin RE, Engelking C, Field M, Ippoliti C, Lazarus HM, Mitchell E, Rubin J, Stiff PJ, Vokes E, Wadler S. Management of cancer treatment-related diarrhea. Issues and therapeutic strategies. J Pain Symptom Manage. 2000 Feb; 19(2):118-29. PMID: 10699539.
      Citations: 17     Fields:    Translation:Humans
    298. Faderl S, Thall PF, Kantarjian HM, Talpaz M, Harris D, Van Q, Beran M, Kornblau SM, Pierce S, Estrov Z. Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia. Clin Cancer Res. 1999 Dec; 5(12):4041-7. PMID: 10632337.
      Citations: 18     Fields:    Translation:HumansCells
    299. Sacchi S, Kantarjian HM, Freireich EJ, O'Brien S, Cortes J, Rios MB, Kornblau S, Giles FJ, Koller C, Gajewski J, Talpaz M. Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia. Leuk Lymphoma. 1999 Nov; 35(5-6):483-9. PMID: 10609785.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    300. Andreeff M, Jiang S, Zhang X, Konopleva M, Estrov Z, Snell VE, Xie Z, Okcu MF, Sanchez-Williams G, Dong J, Estey EH, Champlin RC, Kornblau SM, Reed JC, Zhao S. Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia. 1999 Nov; 13(11):1881-92. PMID: 10557066.
      Citations: 40     Fields:    Translation:HumansCells
    301. Kornblau SM, Qiu YH. Altered expression of retinoblastoma (RB) protein in acute myelogenous leukemia does not result from methylation of the Rb promotor. Leuk Lymphoma. 1999 Oct; 35(3-4):283-8. PMID: 10706451.
      Citations: 1     Fields:    Translation:HumansCells
    302. Champlin R, Khouri I, Kornblau S, Marini F, Anderlini P, Ueno NT, Molldrem J, Giralt S. Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy. Hematol Oncol Clin North Am. 1999 Oct; 13(5):1041-57, vii-viii. PMID: 10553260.
      Citations: 8     Fields:    Translation:Humans
    303. Beran M, Estey E, O'Brien S, Cortes J, Koller CA, Giles FJ, Kornblau S, Andreeff M, Vey N, Pierce SR, Hayes K, Wong GC, Keating M, Kantarjian H. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol. 1999 Sep; 17(9):2819-30. PMID: 10561358.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    304. Le XF, Groner Y, Kornblau SM, Gu Y, Hittelman WN, Levanon D, Mehta K, Arlinghaus RB, Chang KS. Regulation of AML2/CBFA3 in hematopoietic cells through the retinoic acid receptor alpha-dependent signaling pathway. J Biol Chem. 1999 Jul 30; 274(31):21651-8. PMID: 10419474.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    305. Kornblau SM, Thall PF, Estrov Z, Walterscheid M, Patel S, Theriault A, Keating MJ, Kantarjian H, Estey E, Andreeff M. The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res. 1999 Jul; 5(7):1758-66. PMID: 10430080.
      Citations: 24     Fields:    Translation:Humans
    306. Marini FC, Kornblau SM. Production and culture of HSVtk transduced suicidal lymphocytes induces variable changes in the lymphocyte subset composition. Bone Marrow Transplant. 1999 May; 23(9):907-15. PMID: 10338046.
      Citations: 5     Fields:    Translation:HumansCells
    307. Champlin R, Khouri I, Kornblau S, Molldrem J, Giralt S. Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy. Curr Opin Oncol. 1999 Mar; 11(2):87-95. PMID: 10188072.
      Citations: 11     Fields:    Translation:HumansCells
    308. Konopleva M, Mikhail A, Estrov Z, Zhao S, Harris D, Sanchez-Williams G, Kornblau SM, Dong J, Kliche KO, Jiang S, Snodgrass HR, Estey EH, Andreeff M. Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: proliferative and anti-apoptotic activities. Blood. 1999 Mar 01; 93(5):1668-76. PMID: 10029596.
      Citations: 42     Fields:    Translation:HumansCells
    309. Kantarjian HM, O'Brien S, Smith TL, Rios MB, Cortes J, Beran M, Koller C, Giles FJ, Andreeff M, Kornblau S, Giralt S, Keating MJ, Talpaz M. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. J Clin Oncol. 1999 Jan; 17(1):284-92. PMID: 10458244.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    310. Konopleva M, Zhao S, Xie Z, Segall H, Younes A, Claxton DF, Estrov Z, Kornblau SM, Andreeff M. Apoptosis. Molecules and mechanisms. Adv Exp Med Biol. 1999; 457:217-36. PMID: 10500797.
      Citations: 37     Fields:    Translation:HumansAnimals
    311. Beran M, Estey E, O'Brien SM, Giles FJ, Koller CA, Kornblau S, Keating M, Kantarjian HM. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma. 1998 Nov; 31(5-6):521-31. PMID: 9922042.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    312. Estrov Z, Thall PF, Talpaz M, Estey EH, Kantarjian HM, Andreeff M, Harris D, Van Q, Walterscheid M, Kornblau SM. Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood. 1998 Nov 01; 92(9):3090-7. PMID: 9787143.
      Citations: 45     Fields:    Translation:HumansCells
    313. Kornblau SM. The role of apoptosis in the pathogenesis, prognosis, and therapy of hematologic malignancies. Leukemia. 1998 Sep; 12 Suppl 1:S41-6. PMID: 9777895.
      Citations: 4     Fields:    Translation:Humans
    314. Wadler S, Benson AB, Engelking C, Catalano R, Field M, Kornblau SM, Mitchell E, Rubin J, Trotta P, Vokes E. Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J Clin Oncol. 1998 Sep; 16(9):3169-78. PMID: 9738589.
      Citations: 33     Fields:    Translation:Humans
    315. Kornblau SM, Andreeff M, Hu SX, Xu HJ, Patel S, Theriault A, Koller C, Kantarjian H, Estey E, Deisseroth AB, Benedict WF. Low and maximally phosphorylated levels of the retinoblastoma protein confer poor prognosis in newly diagnosed acute myelogenous leukemia: a prospective study. Clin Cancer Res. 1998 Aug; 4(8):1955-63. PMID: 9717825.
      Citations: 1     Fields:    Translation:HumansCells
    316. Le XF, Claxton D, Kornblau S, Fan YH, Mu ZM, Chang KS. Characterization of the ETO and AML1-ETO proteins involved in 8;21 translocation in acute myelogenous leukemia. Eur J Haematol. 1998 Apr; 60(4):217-25. PMID: 9579874.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    317. Deng G, Lane C, Kornblau S, Goodacre A, Snell V, Andreeff M, Deisseroth AB. Ratio of bcl-xshort to bcl-xlong is different in good- and poor-prognosis subsets of acute myeloid leukemia. Mol Med. 1998 Mar; 4(3):158-64. PMID: 9562974; PMCID: PMC2230351.
      Citations: 3     Fields:    Translation:Humans
    318. Sacchi S, Kantarjian HM, Smith TL, O'Brien S, Pierce S, Kornblau S, Beran M, Keating MJ, Talpaz M. Early treatment decisions with interferon-alfa therapy in early chronic-phase chronic myelogenous leukemia. J Clin Oncol. 1998 Mar; 16(3):882-9. PMID: 9508169.
      Citations:    Fields:    Translation:Humans
    319. Kornblau SM, Kantarjian H, O'Brien S, Andreeff M, Koller CA, Beran M, Keating M, Estey E. CECA-cyclophosphamide, etoposide, carboplatin and cytosine arabinoside--a new salvage regimen for relapsed or refractory acute myelogenous leukemia. Leuk Lymphoma. 1998 Jan; 28(3-4):371-5. PMID: 9517508.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    320. Koller CA, Kantarjian HM, Thomas D, O'Brien S, Rios MB, Kornblau S, Murphy S, Keating M. The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia. Leukemia. 1997 Dec; 11(12):2039-44. PMID: 9447817.
      Citations: 14     Fields:    Translation:Humans
    321. Kantarjian HM, O'Brien SM, Keating M, Beran M, Estey E, Giralt S, Kornblau S, Rios MB, de Vos D, Talpaz M. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia. 1997 Oct; 11(10):1617-20. PMID: 9324279.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    322. Sacchi S, Kantarjian HM, O'Brien S, Beran M, Koller C, Pierce S, Kornblau S, Estey E, Keating MJ, Talpaz M. Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemia. Leukemia. 1997 Oct; 11(10):1610-6. PMID: 9324278.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    323. Estey E, Thall P, Kantarjian H, Pierce S, Kornblau S, Keating M. Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia. Leukemia. 1997 Oct; 11(10):1661-4. PMID: 9324286.
      Citations: 31     Fields:    Translation:Humans
    324. Giralt S, Estey E, Albitar M, van Besien K, Anderlini P, O'Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Przepiorka D, Koller C, Kornblau S, Keating M, Kantarjian H, Champlin R, Rond?n G, K?rbling M. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997 Jun 15; 89(12):4531-6. PMID: 9192777.
      Citations: 150     Fields:    Translation:HumansCTClinical Trials
    325. Kornblau SM, Estey E, Madden T, Tran HT, Zhao S, Consoli U, Snell V, Sanchez-Williams G, Kantarjian H, Keating M, Newman RA, Andreeff M. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol. 1997 May; 15(5):1796-802. PMID: 9164187.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    326. Copeland AR, Bueso-Ramos C, Liu FJ, Kornblau SM, Huh YO, Albitar M. Molecular study of hairy cell leukemia variant with biclonal paraproteinemia. Arch Pathol Lab Med. 1997 Feb; 121(2):150-4. PMID: 9126043.
      Citations:    Fields:    Translation:HumansCells
    327. Kornblau SM, Gandhi V, Andreeff HM, Beran M, Kantarjian HM, Koller CA, O'Brien S, Plunkett W, Estey E. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia. 1996 Oct; 10(10):1563-9. PMID: 8847890.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    328. Claxton D, Xie QS, Patel S, Deisseroth AB, Kornblau S. The gene product of CBFB-MYH11. Leukemia. 1996 Sep; 10(9):1479-85. PMID: 8751466.
      Citations: 1     Fields:    Translation:HumansCells
    329. Estey E, Kornblau S, Pierce S, Kantarjian H, Beran M, Keating M. A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. Blood. 1996 Jul 15; 88(2):756. PMID: 8695828.
      Citations: 31     Fields:    Translation:Humans
    330. Sarris A, Cortes J, Kantarjian H, Pierce S, Smith T, Keating M, Koller C, Kornblau S, O'Brien S, Andreeff M. Disseminated intravascular coagulation in adult acute lymphoblastic leukemia: frequent complications with fibrinogen levels less than 100 mg/dl. Leuk Lymphoma. 1996 Mar; 21(1-2):85-92. PMID: 8907274.
      Citations: 7     Fields:    Translation:Humans
    331. Anderlini P, Benjamin RS, Wong FC, Kantarjian HM, Andreeff M, Kornblau SM, O'Brien S, Mackay B, Ewer MS, Pierce SA, et al. Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol. 1995 Nov; 13(11):2827-34. PMID: 7595745.
      Citations: 29     Fields:    Translation:Humans
    332. Kornblau SM, Thall P, Huh YO, Estey E, Andreeff M. Analysis of CD7 expression in acute myelogenous leukemia: martingale residual plots combined with 'optimal' cutpoint analysis reveals absence of prognostic significance. Leukemia. 1995 Oct; 9(10):1735-41. PMID: 7564518.
      Citations:    Fields:    Translation:Humans
    333. Drach J, Kornblau SM, Patel S, Novaes M, Khetan R, Sawaya N, Dorlhiac-Llacer P, Chamone DF, Andreeff M, Del Giglio A, et al. Quantitative expression of proliferating cell nuclear antigen by western blot (PCNAWB) in peripheral blasts correlates with remission induction in patients with acute myelogenous leukemia. Leuk Lymphoma. 1995 Oct; 19(3-4):235-41. PMID: 8535214.
      Citations: 1     Fields:    Translation:Humans
    334. Zhang W, Kornblau SM, Kobayashi T, Gambel A, Claxton D, Deisseroth AB. High levels of constitutive WAF1/Cip1 protein are associated with chemoresistance in acute myelogenous leukemia. Clin Cancer Res. 1995 Sep; 1(9):1051-7. PMID: 9816079.
      Citations: 21     Fields:    Translation:Humans
    335. Gill PS, Harrington W, Kaplan MH, Ribeiro RC, Bennett JM, Liebman HA, Bernstein-Singer M, Espina BM, Cabral L, Allen S, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med. 1995 Jun 29; 332(26):1744-8. PMID: 7760890.
      Citations: 92     Fields:    Translation:HumansCTClinical Trials
    336. Estey EH, Kantarjian HM, O'Brien S, Kornblau S, Andreeff M, Beran M, Pierce S, Keating M. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF). Cytokines Mol Ther. 1995 Mar; 1(1):21-8. PMID: 9384660.
      Citations: 3     Fields:    Translation:Humans
    337. Zhang W, Xu HJ, Kornblau SM, Drach J, Hu SX, Andreeff M, Benedict WF, Deisseroth AB. Growth-factor stimulation reveals two mechanisms of retinoblastoma gene inactivation in human myelogenous leukemia cells. Leuk Lymphoma. 1995 Jan; 16(3-4):191-8. PMID: 7719226.
      Citations:    Fields:    Translation:HumansCells
    338. Kornblau SM, Xu HJ, Zhang W, Hu SX, Beran M, Smith TL, Hester J, Estey E, Benedict WF, Deisseroth AB. Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemia. Blood. 1994 Jul 01; 84(1):256-61. PMID: 8018920.
      Citations: 8     Fields:    Translation:Humans
    339. Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S, Escudier S, Robertson LE, Koller C, Kornblau S, et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol. 1994 Apr; 12(4):671-8. PMID: 7512125.
      Citations: 40     Fields:    Translation:HumansCellsCTClinical Trials
    340. Kornblau SM, Chen N, del Giglio A, O'Brien S, Deisseroth AB. Retinoblastoma protein expression is frequently altered in chronic lymphocytic leukemia. Cancer Res. 1994 Jan 01; 54(1):242-6. PMID: 8261446.
      Citations: 5     Fields:    Translation:HumansCells
    341. Use of retroviral markers to identify efficacy of purging and origin of relapse following autologous bone marrow and peripheral blood cell transplantation in indolent B cell neoplasms (follicular non-Hodgkin's lymphoma or chronic lymphocytic leukemia (CLL) patients). Hum Gene Ther. 1993 Dec; 4(6):821-34. PMID: 8186294.
      Citations:    Fields:    Translation:HumansCells
    342. Deisseroth AB, Kantarjian H, Talpaz M, Champlin R, Reading C, Hanania EG, Fu S, Randhawa GS, Cha Y, Fang X, et al. Molecular approaches to the diagnosis and treatment of cancer. Stem Cells. 1993 Oct; 11 Suppl 3:129-30. PMID: 7905320.
      Citations:    Fields:    Translation:Humans
    343. Kornblau SM, Cortes-Franco J, Estey E. Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia. Leukemia. 1993 Mar; 7(3):378-83. PMID: 8445943.
      Citations: 8     Fields:    Translation:Humans
    344. Estey E, Pierce S, Kantarjian H, O'Brien S, Beran M, Andreeff M, Escudier S, Koller C, Kornblau S, Robertson L, et al. Treatment of myelodysplastic syndromes with AML-type chemotherapy. Leuk Lymphoma. 1993; 11 Suppl 2:59-63. PMID: 7510196.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    345. Deisseroth AB, Hanania EG, Fu S, Claxton D, Andreeff M, Champlin R, Kavanagh J, Hortobagyi G, Holmes F, Reading C, et al. Genetic therapy of human neoplastic disease. J Hematother. 1993; 2(3):373-5. PMID: 7921999.
      Citations:    Fields:    Translation:HumansAnimalsCells
    346. Kornblau SM, Xu HJ, del Giglio A, Hu SX, Zhang W, Calvert L, Beran M, Estey E, Andreeff M, Trujillo J, et al. Clinical implications of decreased retinoblastoma protein expression in acute myelogenous leukemia. Cancer Res. 1992 Sep 01; 52(17):4587-90. PMID: 1511426.
      Citations: 5     Fields:    Translation:Humans
    347. Kornblau SM, Goodacre A, Cabanillas F. Chromosomal abnormalities in adult non-endemic Burkitt's lymphoma and leukemia: 22 new reports and a review of 148 cases from the literature. Hematol Oncol. 1991 Mar-Apr; 9(2):63-78. PMID: 1869243.
      Citations: 6     Fields:    Translation:Humans
    348. Mazzone RW, Kornblau SM. Influence of vascular and transpulmonary pressures on endothelial vesicles in nonedematous and edematous lungs. Microvasc Res. 1983 May; 25(3):343-57. PMID: 6855633.
      Citations:    Fields:    Translation:AnimalsCells
    349. Mazzone RW, Kornblau S. Size of pores of Kohn: influence of transpulmonary and vascular pressures. J Appl Physiol Respir Environ Exerc Physiol. 1981 Sep; 51(3):739-45. PMID: 6895745.
      Citations: 2     Fields:    Translation:Animals
    350. Mazzone RW, Kornblau SM. Pinocytotic vesicles in the endothelium of rapidly frozen rabbit lung. Microvasc Res. 1981 Mar; 21(2):193-211. PMID: 6261089.
      Citations: 5     Fields:    Translation:AnimalsCells
    351. Mazzone RW, Kornblau S, Durand CM. Shrinkage of lung after chemical fixation for analysis of pulmonary structure-function relations. J Appl Physiol Respir Environ Exerc Physiol. 1980 Feb; 48(2):382-5. PMID: 6767671.
      Citations: 4     Fields:    Translation:AnimalsCells
    352. Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFκB/IL1β signaling network. Oncotarget. 7:20054-20067.
    353. PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. Nature Medicine.
    354. Modeling protein expression and protein signaling pathways. Journal of the American Statistical Association. 107:1372-1384.
    355. Phosphorylation of GSK3α/β correlates with activation of AKT and is prognostic for poor overall survival in acute myeloid leukemia patients. BBA Clinical. 4:59-68.
    356. STAT activation status differentiates leukemogenic from nonleukemogenic stem cells in AML and is suppressed by arsenic in t(6;9)-positive AML. Genes and Cancer. 5:378-392.
    357. Future directions in molecular and genetic therapy for Leukemias and solid tumors. Cancer Bulletin. 42:173-180.
    358. Erratum. Leukemia. 28:2427.
    359. Treatment of Newly-Diagnosed AML with Idarubicin + ARA-C. Leukemia and Lymphoma. 7:121.
    360. Low expression of ASH2L protein correlates with a favorable outcome in acute myeloid leukemia. Leukemia and Lymphoma. 1-12.
    361. Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nature Genetics.
    362. Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC). Clinical Lymphoma, Myeloma and Leukemia.
    363. Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target. Leukemia.
    364. Epidermal growth factor receptor is expressed and active in a subset of acute myeloid leukemia. Journal of Hematology and Oncology. 9.
    365. Essential role for cyclic-AMP responsive element binding protein 1 (CREB) in the survival of acute lymphoblastic leukemia. Oncotarget. 6:14970-14981.
    366. Treatment of Newly-Diagnosed AML with idarubicin + ARA-C. Leukemia and Lymphoma. 7.
    367. Are changes in HLA Ags responsible for leukemia relapse after HLA-matched allogeneic hematopoietic SCT?. Bone Marrow Transplantation.
    368. Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse. Blood. 126:2491-2501.
    369. Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia. Cancer Cell. 29:186-200.
    370. Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia. British Journal of Haematology.
    371. Validation of a clinical assay of multi-locus DNA methylation for prognosis of newly diagnosed AML. American Journal of Hematology. 92:E14-E15.
    372. MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/progenitor cells. Oncotarget. 7:55083-55097.
    373. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 29:574-586.
    374. Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Leukemia.
    375. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. Blood. 128:971-981.
    376. HnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic Malignancies. Cancer Cell. 28:486-499.
    377. Erratum. Cancer Cell. 30:183.
    378. p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status. Leukemia.
    379. 151-173.
    380. Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. Cancer Cell. 28:114-128.
    381. Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD). Leukemia.
    382. Progeny clustering. Scientific Reports. 5.
    383. Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. American Journal of Hematology. 92:7-11.
    384. Preclinical activity of the novel B-cell-specific Moloney murine leukemia virus integration site 1 inhibitor PTC-209 in acute myeloid leukemia. Cancer Science. 106:1705-1713.
    385. MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. Cell Reports.
    386. DREAM 9. 108-109.
    387. New directions in the biology and therapy of chronic myeloid leukemia. Leukemia and Lymphoma. 6:89-95.
    388. Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase. The Lancet Haematology.
    389. Self-Enforcing Feedback Activation between BCL6 and Pre-B Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic Leukemia. Cancer Cell. 27:409-425.
    390. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica. 100:927-934.
    391. Gene therapy. Cancer Bulletin. 45:139-145.
    392. Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. Cytometry Part A. 87:346-356.
    393. Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia. Journal of the National Cancer Institute. 108.
    394. Lymphoid neoplasia. Blood. 125:680-686.
    395. Evolution-informed modeling improves outcome prediction for cancers. Evolutionary Applications.
    396. Mixed-phenotype acute leukemia (MPAL) exhibits frequent mutations in DNMT3A and activated signaling genes. Experimental Hematology. 44:740-744.
    397. A Crowdsourcing Approach to Developing and Assessing Prediction Algorithms for AML Prognosis. PLoS Computational Biology. 12.
    398. EphB1 suppression in acute myelogenous leukemia. Molecular Cancer Research. 13:982-992.
    399. Apoptosis regulating proteins as targets of therapy for haematological malignancies. Expert Opinion on Investigational Drugs. 8:2027-2057.
    400. Pleuropericarditis, obliterative bronchiolitis and lymphocytic interstitial pneumonitis after allogeneic haematopoietic stem cell transplantation. BMJ Case Reports.
    401. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nature Communications. 7.
    KORNBLAU's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (974)
    Explore
    _
    Co-Authors (174)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _